WO2020120649A1 - Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule - Google Patents
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule Download PDFInfo
- Publication number
- WO2020120649A1 WO2020120649A1 PCT/EP2019/084788 EP2019084788W WO2020120649A1 WO 2020120649 A1 WO2020120649 A1 WO 2020120649A1 EP 2019084788 W EP2019084788 W EP 2019084788W WO 2020120649 A1 WO2020120649 A1 WO 2020120649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- antigen
- cell
- population
- peptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 127
- 108091007433 antigens Proteins 0.000 title claims abstract description 122
- 102000036639 antigens Human genes 0.000 title claims abstract description 122
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 158
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 77
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 108091054438 MHC class II family Proteins 0.000 claims abstract description 33
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 13
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims abstract description 11
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 9
- 230000003213 activating effect Effects 0.000 claims abstract description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract description 7
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims abstract 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 76
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 33
- 150000007523 nucleic acids Chemical group 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 11
- 210000001163 endosome Anatomy 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 210000003289 regulatory T cell Anatomy 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000013566 allergen Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 2
- 108010063970 HLA-DR15 antigen Proteins 0.000 claims description 2
- 101710089528 T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 69
- 102000004169 proteins and genes Human genes 0.000 abstract description 52
- 241000282414 Homo sapiens Species 0.000 abstract description 28
- 102000043131 MHC class II family Human genes 0.000 abstract description 25
- 210000000170 cell membrane Anatomy 0.000 abstract description 18
- 230000005867 T cell response Effects 0.000 abstract description 14
- 239000012636 effector Substances 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 9
- 230000037361 pathway Effects 0.000 abstract description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract description 7
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 7
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 6
- 102000001398 Granzyme Human genes 0.000 abstract description 5
- 108060005986 Granzyme Proteins 0.000 abstract description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 5
- 210000000265 leukocyte Anatomy 0.000 abstract description 5
- 230000004940 costimulation Effects 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 238000002619 cancer immunotherapy Methods 0.000 abstract description 2
- 102000054189 human CD80 Human genes 0.000 abstract description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 53
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 53
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 53
- 101710176177 Protein A56 Proteins 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 49
- 239000003623 enhancer Substances 0.000 description 45
- 239000000185 hemagglutinin Substances 0.000 description 34
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 32
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 30
- 201000010099 disease Diseases 0.000 description 24
- 230000003211 malignant effect Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 208000006673 asthma Diseases 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 210000002443 helper t lymphocyte Anatomy 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 230000004936 stimulating effect Effects 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 9
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 102000035160 transmembrane proteins Human genes 0.000 description 6
- 108091005703 transmembrane proteins Proteins 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 5
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 108010084313 CD58 Antigens Proteins 0.000 description 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- -1 inhalation Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108010028930 invariant chain Proteins 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100029290 Transthyretin Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 102000002627 4-1BB Ligand Human genes 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000021866 Dressler syndrome Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100029987 Erbin Human genes 0.000 description 2
- 101700035123 Erbin Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 241001663880 Gammaretrovirus Species 0.000 description 2
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 description 2
- 101710172364 Glucose-6-phosphatase 2 Proteins 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000016905 Hashimoto encephalopathy Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102100039093 Insulinoma-associated protein 2 Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100028762 Neuropilin-1 Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 108010090932 Vitellogenins Proteins 0.000 description 2
- 102000004248 Zinc Transporter 8 Human genes 0.000 description 2
- 108090000702 Zinc Transporter 8 Proteins 0.000 description 2
- 238000011467 adoptive cell therapy Methods 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000002707 ameloblastic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000002919 insect venom Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 208000007892 occupational asthma Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010066381 preproinsulin Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 208000034280 venom allergy Diseases 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010054207 Alternaria infection Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150056408 CD58 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 208000010489 Entamoebiasis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 208000004770 Fusariosis Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 206010018260 Giardia infections Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101150078994 La gene Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024179 Legionella infections Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 206010062204 Moraxella infection Diseases 0.000 description 1
- 208000031548 Moraxellaceae Infections Diseases 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000010357 Mullerian Mixed Tumor Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000001676 Polyomavirus Infections Diseases 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010071574 Testicular autoimmunity Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 208000007501 Trichosporonosis Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000007320 autophagy mechanism Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 238000003568 cytokine secretion assay Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 101150020161 flu-2 gene Proteins 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 201000002264 glomangiosarcoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 201000007574 granular cell carcinoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000019697 interleukin-15 production Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000018013 malignant glomus tumor Diseases 0.000 description 1
- 201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 201000002338 malignant struma ovarii Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000309462 non-albicans Candida Species 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000021857 pituitary gland basophilic carcinoma Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention is in the field of immunology.
- the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
- Adoptive cell immunotherapy (ACI) strategies using human functional Ag-specific T lymphocytes (TLs), represent an emerging therapeutic approach to treat cancer but also chronic viral infections. Even if cytotoxic CD8+ TLs (CTLs) are the main effectors of the anti-tumor immune response, CD4+ helper T cells (Th) are crucial to support indirectly the CD8+ responses.
- CTLs cytotoxic CD8+ TLs
- Th CD4+ helper T cells
- 1 CD40 signaling on dendritic cells (DCs) via an interaction with activated Th cells expressing CD40-L increased Ag presentation and costimulatory capacity of DCs and promote efficient CTL priming. 2 IL-2 secretion by Th cells and induction of IL-15 production by DCs is critical for memory CTL responses.
- CD4+ T cells up-regulated CD70 on DCs which in turn interact with CD27 on CTLs delivering a help program that amplify CTL responses and down-regulated exhaustion molecules such as Programmed Death- 1 (PD- l).
- CD4+ TLs can act directly against tumor cells without contribution of CD8+ T cells.
- CD4+ T cells including Thl, Th9 and Thl7 can act directly against tumor by secreting effector cytokines and/or displaying cytotoxic activity against major histocompatibility complex class II (MHC-II) positive tumors. 6-8
- CD4+ TLs in preliminary clinical trials of ACI has shown promising results.
- NY-ESO-1 New York Esophageal Squamous Cell Carcinoma 1
- MHC-II-restricted neoantigens were found in many cancers and represent interesting targets for clinical applications.
- TILs Thl tumor infiltrating lymphocytes
- ACI antigen presenting cells
- AAPCs artificial antigen presenting cells derived from mouse fibroblast NIH/3T3 and expressing a single human leukocyte antigen class II (HLA-II) molecule (HLA-DR1), the co stimulatory molecule CD80 (B7.1) and the two adhesion molecules CD54 (intercellular adhesion molecule-1, ICAM-1) and CD58 (lymphocyte function-associated antigen-3, LFA- 3).
- HLA-II human leukocyte antigen class II
- CD80 co stimulatory molecule
- CD54 intercellular adhesion molecule-1, ICAM-1
- CD58 lymphocyte function-associated antigen-3, LFA- 3
- MHC-II molecules a and b chains are assembled within the endoplasmic reticulum (ER) and associated with the invariant chain (Ii). This heterotrimer migrate, via the Golgi apparatus, to the MHC-II compartment (MIIC). In this specialized endolysosomal compartment, Ii is sequentially degraded by proteases and only the class II invariant chain peptide (CLIP) remains in the MHC-II molecule groove.
- ER endoplasmic reticulum
- Ii invariant chain
- CLIP peptides are then replaced by peptides of higher affinity due to the HLA-DM chaperone protein. These peptides are mainly originated from exogenous Ags that are endocytosed by APCs and degraded by proteases but could arise from endogenous peptide from autophagosomes. Then, peptide/MHC-II complexes will migrate to the APC plasma membrane. 15-17
- the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
- CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy.
- AAPCs artificial antigen presenting cells
- HLA-DR human leukocyte antigen class II molecule
- CD80 costimulation as well as CD54 and CD58 adhesion molecules.
- HLA-DR human leukocyte antigen class II molecule
- CD54 and CD58 adhesion molecules the model was optimized with novel AAPCs HLA- DR1+ (AAPC dr1 ) that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway.
- AAPC DR1 expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein- Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T-cells.
- these two Ag-encoding AAPC cell lines prime specific CD4+ T cells but at lower level than autologous peripheral blood mononuclear cells (PBMCs) used as CPA.
- PBMCs peripheral blood mononuclear cells
- AAPC DR1 targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPC DR1 or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Thl profile and express granzyme B. So, our AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy.
- the first object of the present invention relates to an artificial antigen presenting cell consisting of a eucaryotic cell that is genetically modified to stably express a single MHC class II molecule, at least one accessory molecule and at least one antigen.
- the term "antigen-presenting cell” or “APC” refers to a class of cells capable of presenting antigen to T lymphocytes which recognize antigen when it is associated with a major histocompatibility complex molecule. APCs elicit a T cell response to a specific antigen by processing the antigen into a form that is capable of associating with a major histocompatibility complex molecule on the surface of the APC.
- an "artificial antigen presenting cell” or“AAPC” refers to a eucaryotic cell that has been genetically engineered to function as a professional APC for one or more selected antigens.
- the eucaryotic cell does not express naturally MHC molecules and in particular class II molecules.
- the eucaryotic cell is naturally deficient for the expression of a MHC molecule.
- the eucaryotic cell was previously genetically modified so as to not express a MHC molecule (e.g. by using CRISPR-cas9).
- the eucaryotic cell is naturally deficient for the expression of a molecule that is involved in the formation and transport of the MHC class II molecules.
- the eucaryotic cell was previously genetically modified so as to not express molecule that is involved in the formation and transport of the MHC class II molecules.
- the molecule that is involved in the formation and transport of the MHC class II molecules is the invariant molecule also named as“li” or“CD74”.
- the eucaryotic cell is not a cell deriving from the hematopoietic lineage and can be human, murine, rodentia, insect, or any other mammalian cells.
- the eucaryotic cell is preferably selected from a different species.
- the eucaryotic cell is preferably a murine cell.
- the cells are fibroblasts, and more particularly murine fibroblast (e.g. NIH/3T3 mouse fibroblasts).
- MHC Class II refers to the human Major Histocompatibility Complex Class II proteins, binding peptides or genes.
- the human MHC region also referred to as HLA, is found on chromosome six and includes the Class I region and the Class II region. Within the MHC Class II region are found the DP, DQ and DR subregions for Class II a chain and b chain genes (i.e., DPa, ⁇ Rb, DQa, DC , DRa, and DRb).
- MHC Class II molecule means a covalently or non-covalently joined complex of an MHC Class II a chain and an MHC Class II b chain. MHC class II molecules bind peptides in an intracellular processing compartment and present these peptides on the surface of antigen presenting cells to T cells.
- MHC Class II a chain means a naturally occurring polypeptide, or one encoded by an artificially mutated a gene, essentially corresponding to at least the al and a2 extracellular domains of one of the gene products of an MHC Class II a gene.
- the C-terminal transmembrane and cytoplasmic portions of the a chain are not necessary for antigenic peptide binding in the present invention, they may be omitted while retaining biological activity.
- MHC Class II b chain means a naturally occurring polypeptide, or one encoded by an artificially mutated b gene, essentially corresponding to at least the b ⁇ and b2 extracellular domain of one of the gene products of an MHC Class II b.
- the C- terminal transmembrane and cytoplasmic portions of the b chain are not necessary for antigenic peptide binding in the present invention, they may be omitted while retaining biological activity.
- the MHC class II molecule is selected from the group consisting of HLA-DQ molecules, HLA-DP molecules and HLA-DR molecules. In some embodiments, the MHC class II molecule is selected from the group consisting of HLA-DRl, HLA-DR15 and HLA-DR51 molecules.
- the at least one accessory molecule is selected from the group consisting of co-stimulatory molecules and adhesion molecules.
- co-stimulatory molecule is used herein in accordance with its art recognized meaning in immune T cell activation.
- a“co-stimulatory molecule” refers to a group of immune cell surface receptor/ligands which engage between T cells and antigen presenting cells and generate a stimulatory signal in T cells which combines with the stimulatory signal (i.e.,“co-stimulation”) in T cells that results from T cell receptor (“TCR”) recognition of antigen on antigen presenting cells.
- TCR T cell receptor
- the co-stimulatory molecule is CD80.
- CD80 has its general meaning in the art and refers to B7-1 molecule which is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (T cell activation and survival) and CTLA-4 (T cell inhibition) (Peach, R J; Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley P S (Sep 1995). "Both extracellular immunoglobin- like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28". J.
- adhesion molecule refers to a molecule on the surface of a cell whose primary, or predominant, function is to increase the strength or avidity of the interaction of the cell with another cell (e.g., the interaction between a T cell and an artificial antigen presenting cell of the present invention).
- adhesion molecules include integrins and selectins.
- the adhesion molecule is CD54.
- CD54 has its general meaning in the art and refers to ICAM-1 (Intercellular Adhesion Molecule 1) also known as CD54 (Cluster of Differentiation 54) (Carlson M, Nakamura Y, Payson R, O'Connell P, Leppert M, Lathrop GM, Lalouel JM, White R (May 1988). "Isolation and mapping of a polymorphic DNA sequence (pMCT108.2) on chromosome 18 D18S24". Nucleic Acids Res. 16 (9): 4188.; Katz FE, Parkar M, Stanley K, Murray LJ, Clark EA, Greaves MF (January 1985).
- ICAM-1 is a member of the immunoglobulin superfamily, the superfamily of proteins including antibodies and T-cell receptors. ICAM-1 is a transmembrane protein possessing an amino-terminus extracellular domain, a single transmembrane domain, and a carboxy-terminus cytoplasmic domain. The structure of ICAM- 1 is characterized by heavy glycosylation, and the protein’s extracellular domain is composed of multiple loops created by disulfide bridges within the protein.
- the adhesion molecule is CD58.
- CD58 has its general meaning in the art and refers to lymphocyte function-associated antigen 3 (LFA- 3) which is a cell adhesion molecule expressed on Antigen Presenting Cells (APC), particularly macrophages (Barbosa JA, Mentzer S J, Kamarck ME, Hart J, Biro PA, Strominger JL, Burakoff SJ (April 1986). "Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions". J. Immunol.
- the eucaryotic cell is genetically modified to stably express the CD80, CD54 and CD58 molecules.
- the term“antigen” refers to a whole protein or peptide capable of eliciting a T-cell response.
- the skilled person in the art will be able to select the appropriate antigen, depending on the desired T-cell stimulation.
- the eucaryotic cell is genetically modified to stably express the antigen in a particular compartment of the cell.
- the antigen when the antigen is peptide, it is particularly advantageous to express said peptide is in the endoplasmic reticulum (ER).
- the antigen when the antigen is a protein it is particularly advantageous to express said protein in the endosomes or in the membrane (e.g. a transmembrane protein).
- ER endoplasmic reticulum
- ER refers to a eukaryotic cell organelle that forms an interconnected network of tubules, vesicles, and cisternae within cells that is involved in the production of phospholipids and proteins, among other functions.
- the ER facilitates proper protein folding and quality control (QC) for protein processing.
- QC quality control
- proteins are translocated into the ER lumen after recognition of the signal sequence.
- endosome has its general meaning in the art and refers to a membrane-bound compartment inside eukaryotic cells. It is a compartment of the endocytic membrane transport pathway originating from the trans Golgi membrane.
- the term“signal peptide” or“leader sequence” has its general meaning in the art and refers to a short amino acid sequence that directs a newly synthesized protein through the endoplasmic reticulum, golgi or endosomes.
- the signal peptide is a short peptide, commonly 5-30 amino acids long, present at the N- terminus of the majority of newly synthesized proteins.
- Signal peptides commonly contain a core sequence which is a long stretch of hydrophobic amino acids that has a tendency to form a single alpha-helix.
- the signal peptide may begin with a short positively charged stretch of amino acids, which helps to enforce proper topology of the peptide during translocation.
- the hydrophobic amino acids in the core may, for example be: Alanine (A); Valine (V); Isoleucine (I); Leucine (L); Methionine (M); Phenylalanine (P); Tyrosine (Y); or Tryptophan (W).
- Signal sequences can be detected or predicted using software techniques (see for example, http://www.predisi.de/). A very large number of signal sequences are known, and are available in databases. For example, http://www.signalpeptide.de lists 2109 confirmed mammalian signal peptides in its database.
- the signal peptide is the signal peptide of the T cell surface glycoprotein CD8 alpha chain.
- use of said signal peptide is particularly advantageous for expressing a peptide in the endoplasmic reticulum.
- the signal peptide has the amino acid sequence as forth in SEQ ID NO: 1.
- the eucaryotic cell is genetically modified to stably express the antigen (e.g. peptide) fused to the signal sequence.
- the antigen e.g. peptide
- the antigen is fused directly at its N-terminal end to the signal sequence.
- the term“directly” means that the first amino acid at the N-terminal end of the antigen (e.g. peptide) is fused to the last amino acid at the C-terminal end of the signal peptide.
- the eucaryotic cell when the antigen is a protein, the eucaryotic cell is genetically modified to stably express a protein (i.e. the antigen) at the plasma membrane.
- a protein i.e. the antigen
- the term“plasma membrane” means the phospholipid bilayer structure that comprises the external boundary of a cell.
- Plasma membranes have an external or extracellular face and an internal or intracellular face. Each face has unique features and components (i.e. proteins) associated with it that give it its unique properties.
- adherent cells exhibit polarity, meaning the aspect of the cell that is attached to the basement membrane, called the basal face, has different features than the aspect of the cell that is adluminal, called the apical face.
- the protein comprises a domain that will anchored the protein to the plasma membrane.
- the protein comprises a transmembrane domain, i.e. a protein domain which traverses the cell membrane.
- the protein is a transmembrane protein.
- transmembrane protein is a type of membrane protein spanning the entirety of the plasma membrane to which it is permanently attached in nature. That is, in nature, transmembrane proteins span from one side of a membrane through to the other side of the membrane.
- the antigen is a viral antigen.
- viral antigens include but are not limited to influenza viral Antigens (e.g. hemagglutinin (HA) protein, matrix 2 (M2) protein, neuraminidase), respiratory syncitial virus (RSV) Antigens (e.g. fusion protein, attachment glycoprotein), polio, papillomaviral (e.g. human papilloma virus (HPV), such as an E6 protein, E7 protein, LI protein and L2 protein), Herpes simplex, rabies virus and flavivirus viral Ags (e.g.
- Dengue viral Ags West Nile viral Ags
- hepatitis viral Ags including Ags from HBV and HCV
- human immunodeficiency virus (HIV) Ags e.g. gag, pol or nef
- herpesvirus such as cytomegalovirus and Epstein-Barr virus
- Ags e.g. pp65, IE1, EBNA-1, BZLF-1
- adenovirus Ags e.g. pp65, IE1, EBNA-1, BZLF-1
- the antigen is a bacterial antigen.
- bacterial Ags include but are not limited to those from Streptococcus pneumonia, Haemophilus influenza, Staphylococcus aureus, Clostridium difficile and enteric gram-negative pathogens including Escherichia, Salmonella, Shigella, Yersinia, Klebsiella, Pseudomonas, Enterobacter, Serratia, Proteus, B. anthracis, C. tetani, B. pertussis, S. pyogenes, S. aureus, N meningitidis and Haemophilus influenzae type b.
- the antigen is a fungal or protozoal antigen.
- examples include but are not limited to those from Candida spp., Aspergillus spp., Crytococcus neoformans, Coccidiodes spp., Histoplasma capsulatum, Pneumocystis carinii, Paracoccidiodes brasiliensis, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale , and Plasmodium malar iae.
- the antigen is a tumor-associated Antigen (TAA).
- TAAs include, without limitation, melanoma-associated Ags (Melan-A/MART-1, MAGE-1, MAGE-3, TRP-2, melanosomal membrane glycoprotein gplOO, gp75 and MUC-1 (mucin-1) associated with melanoma); CEA (carcinoembryonic Antigen) which can be associated, e.g., with ovarian, melanoma or colon cancers; folate receptor alpha expressed by ovarian carcinoma; free human chorionic gonadotropin beta (hCGP) subunit expressed by many different tumors, including but not limited to ovarian tumors, testicular tumors and myeloma; HER-2/neu associated with breast cancer; NY-ESO-1 of metastatic carcinomas, encephalomyelitis antigen HuD associated with small-cell lung cancer; tyrosine hydroxylase associated with neuroblastoma; prostate-
- the antigen is an auto-antigen.
- auto- antigen means any self-antigen arising from the own body tissues which is mistakenly recognized by the immune system as being foreign. Auto-antigens comprise, but are not limited to, cellular proteins, phosphoproteins, cellular surface proteins, cellular lipids, nucleic acids, glycoproteins, including cell surface receptors.
- auto-antigens include but are not limited to preproinsulin (PPI), glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 (IA-2), islet-specific glucose-6-phosphatase catalytic-subunit-related protein (IGRP), zinc transporter 8 (ZnT8) and chromogranin A for T1D; myeloperoxydase and proteinase 3 for granulomatosis with polyangiitis; myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in multiple sclerosis; and gliadins in celiac disease
- PPI preproinsulin
- GAD glutamic acid decarboxylase
- IA-2 insulinoma-associated protein 2
- IGRP islet-specific glucose-6-phosphatase catalytic-subunit-related protein
- ZnT8 zinc transporter 8
- chromogranin A for T1D
- the antigen is an allergen.
- allergen generally refers to an antigen or antigenic portion of a molecule, usually a protein, which elicits an allergic response upon exposure to a subject.
- the subject is allergic to the allergen as indicated, for instance, by the wheal and flare test or any method known in the art.
- a molecule is said to be an allergen even if only a small subset of subjects exhibit an allergic immune response upon exposure to the molecule.
- the AAPC of the present invention may be prepared according to any well-known method in the art.
- the skilled would refer to the international patent application WO 2001094944; Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigenpresenting cells. Nat Biotechnol 2000; 18:405-9.
- the AAPCs of the present are typically produced ex vivo by the insertion of one or more recombinant or synthetic nucleic acid sequences (genes) encoding the molecules of interest, such that the molecules are expressed in effective amounts in the recipient subject cell.
- nucleic acid sequences can be obtained by conventional methods well known to those skilled in the art.
- said nucleic acid is a DNA or RNA molecule.
- Useful nucleic acid molecules for constructing the AAPCs of the present invention e.g., selected antigens, MHC molecules, adhesion molecules, costimulatory molecules, etc. are cloned into a vector before they are introduced into the eucaryotic cell and optionally are passage in cells other than AAPCs to generate useable quantities of these nucleic acids.
- vector means the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a eucaryotic cell, so as to transform the cell and promote expression (e.g. transcription and translation) of the introduced sequence.
- Suitable vectors for the invention may be plasmid or viral vectors, including baculoviruses, adenoviruses, poxviruses, adenoassociated viruses (AAV), and retrovirus vectors (Price et al, 1987, Proc. Natl. Acad. Sci.
- Plasmid expression vectors include plasmids including pBR322, pUC or Bluescript.TM. (Stratagene, San Diego, Calif). Typically retroviral vectors are used for introducing the nucleic acid of interest into the eucaryotic cell.
- the retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse- transcription (Coffin, 1990, in Fields et al., Ceds, Virology, Raven Press, New York, pp. 1437- 1500).
- the resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins.
- the integration results in the retention of the viral gene sequences in the eucaryotic cell and its descendants.
- the retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively.
- a sequence found upstream from the gag gene functions as a signal for packaging of the genome into virions.
- Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the subject cell genome (Coffin, supra).
- LTR long terminal repeat
- Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, 1990, Blood 76:271). Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al.
- retroviruses examples include pLJ, pWE and pEM which are well known to those skilled in the art.
- suitable packaging virus cell lines include Crip, Cre, 2 and Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al., 1985, Science, 230: 1395- 1398; Danos, et al., 1988, Proc. Natl. Acad. Sci.
- Retroviral vectors require target cell division in order for the retroviral genome (and foreign nucleic acid inserted into it) to be integrated into the subject genome to stably introduce nucleic acid into the cell. Thus, it may be necessary to stimulate replication of the target cell.
- gamma-retroviral vector is used (Tobias Maetzig, Melanie Galla, Christopher Baum, and Axel Schambach Gammaretroviral Vectors: Biology, Technology and Application. Viruses. Jun 2011; 3(6): 677- 713.).
- a Gamma-retrovirus-derived SFG vector as described in EXAMPLE is used.
- a plurality of vectors are employed, each vector encoding one molecule of interest (i.e. the MHC class II molecule, the accessory molecule or the antigen).
- the expression of the exogenous nucleic acid is under the control of a promoter.
- promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40 (Mizukami T. et al. 1987), LTR promoter and enhancer of Moloney mouse leukemia virus (Kuwana Y et al. 1987), promoter (Mason JO et al. 1985) and enhancer (Gillies SD et al. 1983) of immunoglobulin chain and the like.
- a vector comprising a nucleic acid sequence encoding for the signal peptide operatively linked to a nucleic acid sequence encoding for the antigen (e.g. peptide) is used to stably express the antigen peptide into the endoplasmic reticulum of the eucaryotic cell.
- the nucleic acid sequence encoding for the signal peptide consists of the nucleic acid sequence as set forth in SEQ ID NO: 2.
- operably linked or “operatively linked” are used interchangeably herein, and refer to the functional relationship of the nucleic acid sequences and indicates that two or more DNA segments are joined together such that they function in concert for their intended purposes.
- the expression vectors comprise one or more regulatory elements to drive and/or enhance expression of upstream or downstream nucleic acids.
- regulatory sequences are selected on the basis of the cells (e.g., types of AAPCs) to be used for expression, and are operatively linked to a nucleic acid sequence to be expressed.
- the term "regulatory elements” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory elements are described, for example, in Goeddel; 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA.
- Regulatory elements include those which direct expression of a nucleotide sequence in many types of subject cells as well as those which direct expression of the nucleotide sequence only in certain subject cells (e.g., tissue-specific regulatory sequences). Regulatory elements also include those which direct constitutive expression of an operatively linked nucleic acid sequence and those which direct inducible expression of the nucleic acid sequence.
- Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest.
- Some eukaryotic promoters and enhancers have a broad range of cells in which they can activate and/or modulate transcription while others are functional only in a limited subset of cell types (See e.g., Voss et al, 1986, Trends Biochem. Sci., 11 :287; and Maniatis et ah, supra, for reviews).
- the SV40 early gene enhancer is very active in a wide variety of cell types from many eucaryotic species and has been widely used for the expression of proteins in mammalian cells (Dijkema et al, 1985, EMBO J. 4:761).
- promoter/enhancer elements active in a broad range of mammalian cell types are those from the human elongation factor la gene (Uetsuki et al., 1989, J. Biol. Chem., 264:5791; Kim et al., 1990, Gene, 91 :217; and Mizushima, et al, 1990, Nagata, Nuc. Acids. Res., 18:5322) and the long terminal repeats of the Rous sarcoma virus (Gorman et al., 1982, Proc. Natl. Acad. Sci.
- Suitable promoters which may be employed include, but are not limited to, TRAP promoters, adenoviral promoters, such as the adenoviral major late promoter; the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter, heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; ITRs; the b- actin promoter; and human growth hormone promoters.
- TRAP promoters such as the adenoviral major late promoter
- CMV cytomegalovirus
- RSV respiratory syncytial virus
- inducible promoters such as the MMT promoter, the metallothione
- the promoter also may be the native promoter that controls the nucleic acid encoding the polypeptide and the sequences of native promoters may be found in the art (see Agrawal et al., 2000, J. Hematother. Stem Cell Res., 795- 812; Coumoyer et al., 1993, Annu. Rev. Immunol., 11 :297-329; van de Stolpe et al., 1996, J. Mol. Med., 74: 13-33; Herrmann, 1995, J. Mol. Med., 73 : 157-63).
- enhancer sequences can also be used in the instant invention including but not limited to: Immunoglobulin Heavy Chain enhancer; Immunoglobulin Light Chain enhancer; T- Cell Receptor enhancer; HLA DQa and DQP enhancers ; b-Interferon enhancer; interleukin-2 enhancer; Interleukin-2 Receptor enhancer;; MHC Class II HLA-DRa enhancer ; b-Actin enhancer; Muscle Creatine Kinase enhancer; Prealbumin (Transthyretin) enhancer; Elastase I enhancer; Metallothionein enhancer; Collagenase enhancer; Albumin Gene enhancer; a-Fetoprotein enhancer; b-Globin enhancer; c-fos enhancer; c-HA-ras enhancer; Insulin enhancer; Neural Cell Adhesion Molecule (NCAM) enhancer; al -Antitrypsin enhancer; H2B (TH2B) Histone enhancer;
- the artificial antigen presenting cell of the present invention may find applications and uses in a wide number of contexts.
- a further object of the present invention relates to a method of activating and/or amplifying a population of antigen-specific CD4+ T cells comprising the steps of coculturing a population of a T cells with the population of artificial antigen presenting cells of the present invention.
- the population of AAPCs is irradiated by any conventional method well known in the art before incubation with the population of CD4 T cells.
- the population of CD4+ T cells is substantially purified by magnetic bead purification systems such as those available in the art, e.g., Miltenyi beads (Myltenyi Biotec) and Dynabead systems (Dynal Biotech) or with cell sorting procedures, such as FACS-based methods, or other appropriate cell sorting devices and methodologies.
- the population of CD4+ T cells is purified from a PBMC sample.
- PBMC or“peripheral blood mononuclear cells” or“unfractionated PBMC”, as used herein, refers to whole PBMC, i.e.
- the PBMC sample according to the invention has not been subjected to a selection step to contain only adherent PBMC (which consist essentially of >90% monocytes) or non-adherent PBMC (which contain T cells, B cells, natural killer (NK) cells, NK T cells and DC precursors).
- adherent PBMC which consist essentially of >90% monocytes
- non-adherent PBMC which contain T cells, B cells, natural killer (NK) cells, NK T cells and DC precursors.
- a PBMC sample according to the invention therefore contains lymphocytes (B cells, T cells, NK cells, NKT cells), monocytes, and precursors thereof.
- these cells can be extracted from whole blood using Ficoll, a hydrophilic polysaccharide that separates layers of blood, with the PBMC forming a cell ring under a layer of plasma.
- PBMC can be extracted from whole blood using a hypotonic lysis buffer which will preferentially lyse red blood cells.
- the population of CD4+ T cells and the population of AAPC are cocultured for a time sufficient to activate and enrich for a desired population of activated memory CD4+ T cells.
- the T cells and the AAPCs of the present invention are contacted for 5, 6, 7, 8, 9, 10, 11, or 12, days.
- the T cells and the AAPCs of the present invention are contacted for at least 7 days.
- Any culture medium suitable for growth, survival and differentiation of T cells is used for the coculturing step.
- it consists of a base medium containing nutrients (a source of carbon, aminoacids), a pH buffer and salts, which can be supplemented with serum of human or other origin and/or growth factors and/or antibiotics to various cytokines could be added.
- the base medium can be RPMI 1640, DMEM, IMDM, X- VIVO or AIM-V medium, all of which are commercially available standard media.
- the method of the present invention is particularly suitable for activating and/or amplifying a population of antigen-specific memory CD4+ T cells.
- memory CD4+ T cell has its general meaning in the art and to a subset of CD4+ T cells that are specific to the antigen they first encountered and can be called upon during the secondary immune response. Typically, memory CD4+ T cells are characterized by the expression at their cell surface of CD45RO.
- the method further comprises the step of isolating the population of antigen-specific CD4+ T cells.
- Methods for isolating the population of antigen-specific CD4+ T cells are conventional to the skilled person.
- the method may use Class II multimers. With this procedure, Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g., Prolmmune MHC Class I Pentamers, Class II Ultimers; or Immudex MHC Dextramers) or in-house generated ones, e.g., from the NIH Tetramer Facility at Emory University, USA; from Dr. S.
- commercially available reagents e.g., Prolmmune MHC Class I Pentamers, Class II Ultimers; or Immudex MHC Dextramers
- in-house generated ones e.g., from the NIH Tetramer Facility at Emory University, USA; from Dr. S.
- the method is based on the detection of the upregulation of activation markers. With this procedure, Antigen-specific T helper cell responses are detected by their differential expression of activation markers exposed on the membrane following Ag- recognition.
- the method may consist in a cytokine capture assay. This system developed by Miltenyi Biotech is a valid alternative to the ELISpot to visualize Antigen- specific T helper cells according to their cytokine response.
- the method may consist of a CD 154 assay. This procedure has been described in detail [Chattopadhyay et al, Nat.Med. 11 : 1113, 2005; Frentsch et al., Nat.Med. 11 : 1118, 2005] It is limited to detection of Ag-specific CD4+ T cells.
- the method may consist in a CFSE dilution assay. This procedure detects Antigen-specific T helper cells according to their proliferation following Ag recognition [Mannering et al., J.ImmunolMethods 283 : 173, 2003] Other methods suitable for detecting cell proliferation (e.g. BrdU incorporation, Ki67 expression) may also be used. Besides being suitable for detecting the population of antigen-specific CD4+ T cells, said methods allows the direct sorting and/or cloning of the T cells of interest.
- the method of the present invention is particularly suitable for generating antigen-specific memory Thl, Th2 or Thl7 cells.
- T helper cell (“Th cell”) refers to a subset of lymphocytes which complete maturation in the thymus and have various roles in the immune system, including the identification of specific foreign antigens in the body and the activation and deactivation of other immune cells. By this, T helper cells are involved in almost all adaptive immune responses. Mature Th cells are believed to always express the surface protein CD4 and are therefore also termed CD4+ T cells.
- the term“Thl cell” and“Th2 cell” mean a type-1 helper T cell and a type-2 helper T cell, respectively.
- Thl cells produce high levels of the proinflammatory cytokine IFNy Polarization in said T cell subset can be carried out by any conventional method well known in the art that typically consists in incubation the T cells with at least one cytokine (e.g. IL-12 for Thl cells).
- cytokine e.g. IL-12 for Thl cells
- the term“Thl7 cells” has its general meaning in the art and refers to a subset of T helper cells producing interleukin 17 (IL-17).“A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage”. Nat. Med. 13 (2): 139-145, 2007).
- the term“IL-17” has its general meaning in the art and refers to the interleukin-17A protein.
- Thl7 cells are characterized by classical expression of Th cell markers at their cell surface such as CD4, and by the expression of IL-17.
- a Thl7 cell is a IL-17+
- the method of the present invention further comprise a step consisting of polarizing the antigen-specific CD4+ T cells into a population of antigen-specific T regulatory cells.
- T regulatory cell denotes a T lymphocyte endowed with a given antigen specificity imprinted by the TCR it expresses and with regulatory properties defined by the ability to suppress the response of conventional T lymphocytes or other immune cells.
- responses include, but are not limited to, cytotoxic activity against antigen-presenting target cells and secretion of different cytokines.
- Tregs include, but are not limited to: inducible and thymic-derived Tregs, as characterized by different phenotypes such as CD4+CD25+/high, CD4+CD25+/highCD127-/low alone or in combination with additional markers that include, but are not limited to, FoxP3, neuropilin-1 (CD304), glucocorticoid-induced TNFR-related protein (GITR), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD 152); T regulatory type 1 cells; T helper 3 cells. All these Tregs can be obtained either upon direct ex vivo purification or upon in vitro expansion or differentiation from the population of antigen-specific CD4+ T cells of the present invention.
- additional markers include, but are not limited to, FoxP3, neuropilin-1 (CD304), glucocorticoid-induced TNFR-related protein (GITR), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD 152); T regulatory type 1 cells;
- the polarization consists in incubating the antigen-specific T helper cells with an amount of at least one cytokine such as TGFbeta.
- the population of antigen-specific CD4+ T cells of the present invention is particularly suitable for adoptive cell therapy in subjects in need thereof.
- the population of antigen-specific CD4+ T cells of the present invention are suitable for the treatment of cancer.
- cancer has its general meaning in the art and includes, but is not limited to, solid tumors and blood-borne tumors.
- the term cancer includes diseases of the skin, tissues, organs, bone, cartilage, blood and vessels.
- the term “cancer” further encompasses both primary and metastatic cancers.
- cancers that may be treated by methods and compositions of the invention include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus.
- the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acid
- the population of antigen-specific CD4+ T cells of the present invention are suitable for treating subjects afflicted with, or at risk of developing, an infectious disease, including but not limited to viral, retroviral, bacterial, and protozoal infections, etc.
- an infectious disease including but not limited to viral, retroviral, bacterial, and protozoal infections, etc.
- Subjects that can be treated include immunodeficient patients afflicted with a viral infection, including but not limited to CMV, EBV, adenovirus, BK polyomavirus infections in transplant patients, etc.
- the subjects at risk of developing an infectious disease include patients undergoing hematopoietic stem cell transplantation using peripheral blood or CB precursors.
- the term "patient undergoing hematopoietic stem cell transplantation (HSCT)” refers to a human being who has to be transplanted with HSC graft. Typically, said patient is affected with a disorder which can be cured by HSCT. In some embodiments, the patient undergoing HSCT is affected with a disorder selected from the group consisting of leukemia, lymphoma, myeloproliferative disorders, myelodysplastic syndrome (MDS), bone marrow (BM) failure syndromes, congenital immunodeficiencies, enzyme deficiencies and hemoglobinopathies. In some embodiments, the HSCT is an allogeneic HSCT.
- the term “allogeneic” refers to HSC deriving from, originating in, or being members of the same species, where the members are genetically related or not.
- An “allogeneic transplant” refers to transfer of cells or organs from a donor to a recipient, where the recipient is the same species as the donor. Allogeneic transplantation involves infusion of donor stem cells, typically using a donor that matches the recipient's MHC. However, matched unrelated donor (MUD) transplants are also associated with a stronger graft versus host reaction, and thus result in higher mortality rates.
- the HSCT is an autologous HSCT.
- autologous refers to deriving from or originating in the same subject or patient.
- an “autologous transplant” refers to collection and retransplant of a subject's own cells or organs. Autologous transplantation involves infusion of a recipient's own cells following myeloablative treatment. Autologous cell transplants minimize the risk of graft versus host disease (GVHD) and result in reduced complications.
- GVHD graft versus host disease
- the population of antigen-specific CD4+ T cells of the present invention are particularly suitable for preventing bacterial, viral, protozoal and/or fungal infection following CB HSCT.
- Non-limiting examples of viral infections include Herpes simplex virus (HSV) infections, CMV infections, Varicella-zoster virus (VZV) infections, Human herpes virus 6 (HHV6) infections, EBV infections, respiratory virus infections (such as respiratory syncytial virus (RSV), parainfluenza virus, rhinovirus, and influenza virus) and adenovirus infections.
- Non-limiting examples of bacterial infections include Gram-negative bacteria infections such as Escherichia (e.g. Escherichia coli), Salmonella, Shigella, and other Enterobacteriaceae, Pseudomonas (e.g. Pseudomonas aeruginosa), Moraxella, Helicobacter, and Legionella infections.
- Non-limiting examples of protozoal infections include Giardia infections (e.g. Giardia lamblia), Entamoeba infections (e.g. Entamoeba histolytica) and Toxoplasma (e.g. Toxoplasma gondii).
- Non-limiting examples of fungal infections include Aspergillus infection (e.g. Aspergillus fumigatus), Candida infection (e.g. Candida albicans and non-albicans Candida) and other emerging fungal infections including Trichosporon, Alternaria, Fusarium, and Mucorales infections.
- the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of autoimmune diseases.
- autoimmune disease refers to the presence of an autoimmune response (an immune response directed against an auto- or self-antigen) in a subject.
- Autoimmune diseases include diseases caused by a breakdown of self-tolerance such that the adaptive immune system, in concert with cells of the innate immune system, responds to self- antigens and mediates cell and tissue damage.
- autoimmune diseases are characterized as being a result of, at least in part, a humoral and/or cellular immune response.
- autoimmune disease examples include, without limitation, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti- GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal and neuronal neuropathies, Behcet's disease, bullous pemphigoid, autoimmune cardiomyopathy, Castleman disease, celiac
- the autoimmune disease is selected from the group consisting of rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (lupus or SLE), myasthenia gravis, multiple sclerosis, scleroderma, Addison's Disease, bullous pemphigoid, pemphigus vulgaris, Guillain-Barre syndrome, Sjogren syndrome, dermatomyositis, thrombotic thrombocytopenic purpura, hypergammaglobulinemia, monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia (WM), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Hashimoto's Encephalopathy (HE), Hashimoto's Thyroiditis, Graves' Disease, Wegener's Granulomatosis [Granulomatosis with Poly angiitis (GPA)].
- the autoimmune disease is selected from the group consisting of
- the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of allergies.
- allergy generally refers to an inappropriate immune response characterized by inflammation and includes, without limitation, food allergies, respiratory allergies and other allergies causing or with the potential to cause a systemic response such as, by way of example, Quincke’s oedema and anaphylaxis.
- the term encompasses allergy, allergic disease, hypersensitive associated disease or respiratory disease associated with airway inflammation, such as asthma or allergic rhinitis.
- the method of the present invention is effective in preventing, treating or alleviating one or more symptoms related to anaphylaxis, drug hypersensitivity, skin allergy, eczema, allergic rhinitis, urticaria, atopic dermatitis, dry eye disease, allergic contact allergy, food hypersensitivity, allergic conjunctivitis, insect venom allergy, bronchial asthma, allergic asthma, intrinsic asthma, occupational asthma, atopic asthma, acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD).
- anaphylaxis drug hypersensitivity
- skin allergy eczema
- allergic rhinitis urticaria
- atopic dermatitis dry eye disease
- COPD chronic obstructive pulmonary disease
- Hypersensitivity associated diseases or disorders that may be treated by the method of the present invention include, but are not limited to, anaphylaxis, drug reactions, skin allergy, eczema, allergic rhinitis, urticaria, atopic dermatitis, dry eye disease [or otherwise referred to as Keratoconjunctivitis sicca (KCS), also called keratitis sicca, xerophthalmia], allergic contact allergy, food allergy, allergic conjunctivitis, insect venom allergy and respiratory diseases associated with airway inflammation, for example, IgE mediated asthma and non-IgE mediated asthma.
- KCS Keratoconjunctivitis sicca
- the respiratory diseases associated with airway inflammation may include, but are not limited to, rhinitis, allergic rhinitis, bronchial asthma, allergic (extrinsic) asthma, non-allergic (intrinsic) asthma, occupational asthma, atopic asthma, exercise induced asthma, cough- induced asthma, acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD).
- rhinitis allergic rhinitis
- bronchial asthma allergic (extrinsic) asthma
- non-allergic (intrinsic) asthma non-allergic (intrinsic) asthma
- occupational asthma atopic asthma
- exercise induced asthma exercise induced asthma
- cough- induced asthma cough- induced asthma
- COPD chronic obstructive pulmonary disease
- the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of immune reactions against a grafted tissue or grafted hematopoietic cells or grafted blood cells.
- a graft selected from the group consisting of heart, kidney, lung, liver, pancreas, pancreatic islets, brain tissue, stomach, large intestine, small intestine, cornea, skin, trachea, bone, bone marrow, muscle, or bladder.
- the method of the present invention is also particularly suitable for preventing or suppressing an immune response associated with rejection of a donor tissue, cell, graft, or organ transplant by a recipient subject.
- Graft-related diseases or disorders include graft versus host disease (GVHD), such as associated with bone marrow transplantation, and immune disorders resulting from or associated with rejection of organ, tissue, or cell graft transplantation (e.g., tissue or cell allografts or xenografts), including e.g., grafts of skin, muscle, neurons, islets, organs, parenchymal cells of the liver, etc.
- GVHD graft versus host disease
- HVGD Host-Versus-Graft- Disease
- GVHD Graft- Versus-Host-Disease
- the population of antigen-specific CD4+ T cells may be administered to the subject before, during and/or after transplantation (e.g., at least one day before transplantation, at least one day after transplantation, and/or during the transplantation procedure itself). In some embodiments, the population of antigen-specific CD4+ T cells may be administered to the subject on a periodic basis before and/or after transplantation.
- treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- the general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer during a maintenance regimen, or both.
- maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at regular intervals, e.g., daily, weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
- the population of antigen-specific CD4+ T cells of the present invention can be utilized in methods and compositions for adoptive cell therapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure. See, e.g., US Patent Application Publication No. 2003/0170238 to Gruenberg et al; see also US Patent No. 4,690,915 to Rosenberg.
- the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount.
- Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized.
- the infusion medium can be supplemented with human serum albumin.
- a treatment-effective amount of cells in the composition is dependent on the relative representation of the antigen-specific T helper cells with the desired specificity, on the age and weight of the recipient, on the severity of the targeted condition and on the immunogenicity of the targeted Ags. These amount of cells can be as low as approximately 103/kg, preferably 5x103/kg; and as high as 107/kg, preferably 108/kg.
- the number of cells will depend upon the ultimate use for which the composition is intended, as will the type of cells included therein. For example, if cells that are specific for a particular Ag are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and 90-95% of such cells. If frequencies of antigen-specific T cells are insufficient, T cell lines can be enriched by cell sorting using tetramers or dextramers®; or MACS® cytokine secretion assay (Miltenyi Biotec) For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 ml or less, even 250 ml or 100 ml or less. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed the desired total amount of cells.
- administering refers to administration of the compounds as needed to achieve the desired effect. Administration may include, but is not limited to, oral, sublingual, intramuscular, subcutaneous, intravenous, transdermal, topical, parenteral, buccal, rectal, and via injection, inhalation, and implants.
- a further object of the present invention relates to a method of identifying a population of CD4+ T cells within a test population of T cells comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i) and iii) detecting whether a population of CD4+ T cells is activated and/or amplified.
- the population of T cells is isolated from a biological sample obtained from a subject/patient.
- tissue sample to any biological sample obtained from the purpose of evaluation in vitro.
- the sample is typically a tissue sample or a body fluid sample.
- tissue sample includes sections of tissues such as biopsy or autopsy samples and frozen sections taken for histological purposes.
- the tissue sample is a tumor tissue sample.
- tumor tissue sample means any tissue tumor sample derived from the patient. Said tissue sample is obtained for the purpose of the in vitro evaluation.
- the tumor sample may result from the tumor resected from the patient.
- the tumor sample may result from a biopsy performed in the primary tumour of the patient or performed in metastatic sample distant from the primary tumor of the patient.
- body fluids are blood, serum, plasma, amniotic fluid, brain/spinal cord fluid, liquor, cerebrospinal fluid, sputum, throat and pharynx secretions and other mucous membrane secretions, synovial fluids, ascites, tear fluid, lymph fluid and urine. More particularly, the sample is a blood sample.
- blood sample means a whole blood sample obtained from the patient.
- the method can be used to screen for the ability of a test agent (e.g. a vaccine.) to elicit a particular antigen-specific population of CD4+ T cells.
- a test agent e.g. a vaccine.
- This method would involve administering to the subject the test agent, obtaining sample comprising a population of T cells and performing the method of the present invention for determining whether the antigen-specific population of CD4+ T cells can be activated and/or amplified.
- the method of the present invention is also particularly suitable for determining if a subject has been exposed to (or is presently exposed to) one or more particular antigens.
- the method of the invention can be used to see if a subject has any immunity left from previous vaccinations/immunizations.
- Known antigens associated with a given vaccine for example, can be used to detect and quantitate any effector cells present in a biological sample obtained from the subject.
- the method of the present invention is also particular suitable for optimizing an antigen for use in a vaccine.
- the method typically involves providing a plurality of antigens that are candidates for the vaccine; screening the antigens using any of the method of the present invention; and selecting an antigen that is capable of activating and/or the antigen-specific population of CD4+ T cells.
- the method of the present invention may also find application in diagnosis.
- the method of the present invention is particularly suitable for diagnosing infectious diseases, cancer and autoimmune diseases.
- the method of the present invention can be used to detect one or more antigen specific T cell responses which are correlated with the disease.
- the method of the present invention is also particularly suitable for monitoring immune therapy.
- the term“monitoring immune therapy” refers to measurement of changes in T cell responses induced in a given subject following in vivo administration of immune modulating agents. For monitoring applications, different types of situations are found, according to the type of disease.
- immune modulatory therapies can be used to blunt pathological immune responses.
- immune modulatory agents is an immunosuppressive drug.
- immunosuppressive treatment refers to any substance capable of producing an immunosuppressive effect, e.g., the prevention or diminution of the immune response and in particular the prevention or diminution of the production of Ig.
- Immunosuppressive drugs include, without limitation thiopurine drugs such as azathioprine (AZA) and metabolites thereof; nucleoside triphosphate inhibitors such as mycophenolic acid (Cellcept) and its derivative (Myfortic); derivatives thereof; prodrugs thereof; and combinations thereof.
- 6-mercaptopurine (“6-MP")
- cyclophosphamide mycophenolate
- prednisolone sirolimus
- dexamethasone rapamycin
- FK506, mizoribine azothioprine
- tacrolimus Other examples also include calcineurin inhibitors and corticosteroids.
- corticosteroids examples include flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort and betamethasone corticosteroids, for example, cortisone, hydrocortisone, methylprednisolone, prednisone, prednisolone, betamethesone, beclomethasone dipropionate, budesonide, dexamethasone sodium phosphate, flunisolide, fluticasone propionate, triamcinolone acetonide, betamethasone, fluocinolone, fluocinonide, betamethasone dipropionate, betamethasone valerate, desonide, desoximetasone, fluocinolone, triamcinolone, triamcinolone acetonide, clobetasol propionate, and dexamethasone.
- cortisone hydrocortisone
- the method of the present invention is particularly suitable for determining whether a subject is at risk of relapse.
- relapse refers to the return of signs and symptoms of a disease after a subject has enjoyed a remission after a treatment.
- a further object of the present invention relates to a method of determining identifying and/or characterizing the T cell epitopes of an antigen comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i), iii) detecting whether a population of CD4+ T cells is activated and/or amplified, iv) selecting the population of artificial antigen presenting cells that is capable of activating and/or amplifying the population of CD4+ T cells, v) recovering and characterizing the peptides from the MHC class II molecules wherein said peptides represent the T cell epitopes of the antigen.
- peptides are identified by the classical method of HLA-peptide complex extraction, peptide elution and subsequent peptide epitope identification by sequencing mass spectrometry.
- the method of the present invention comprises the steps of lyzing the population of artificial antigen presenting cells, recovering the MHC class II molecules typically in an immune affinity step, recovering the peptides from the MHC class II molecules and analyzing by mass spectrometry said peptides.
- the peptides are analyzed by LC-MS or LC-MS/MS that are the combination of liquid chromatography (LC) with mass spectrometry (MS).
- MS means you only analyze your precursor ion (as generated in the source) for example in an iontrap, a quadrupole or time-of-flight Massspec.
- MS/MS is the combination of two mass analyzers in one mass spectrometry instrument. The first MS filters for the precursor ion followed by a fragmentation of the precursor ion with high energy and e.g. nitrogen gas. A second mass analyzer is then filtering for the product ions, generated by the fragmentation. This is usually done in a triple quadrupole MS (QQQ) or a QTOF.
- QQQ triple quadrupole MS
- QTOF QTOF
- the method of the present invention is particularly suitable for determining protein antigenicity, identifying which antigens from an oncogene, virus, bacteria, pathogen, vaccine or other vector are actually presented by antigen presenting cells, discovering new peptide targets for cancer and infectious disease interventions, understanding the impact of protein modifications on immune responses...
- the method of the present invention is thus particularly suitable for the in vitro study of the immunogenicity (or tolerogenicity) of therapeutic proteins.
- therapeutic proteins refers to protein or peptide compounds of any aminoacid length which are administered or are planned to be administered in vivo to human subjects to achieve a therapeutic effect.
- therapeutic proteins are antibodies of different species (either in their native form or partially/fully humanized), cytokines, hormones or hormone analogues, coagulation factors, enzymes, bacterial or viral proteins.
- Such proteins are not limited to natural ones, but also include modified proteins or chimeric constructs, obtained for example by changing selected aminoacid sequences or by fusing portions of different proteins.
- One first therapeutic setting concerns the use of disease-associated antigens for in vivo administration, with the aim of inducing a tolerogenic effect (e.g., in the case of autoimmune diseases) or an immunogenic effect (e.g., in the case of cancer or infectious diseases). It is important to first evaluate in vitro the potential to achieve said desired therapeutic effect.
- the aim is not to induce immunogenic responses of any kind to the administered protein, but rather to avoid such responses so to allow said protein to achieve the therapeutic effect for which it is designed.
- Example of such settings include, without being limited to, cytokine-based immune therapies, hormone replacement therapies and replacement therapies for coagulation factors (e.g., Factor VIII in Haemophilia A) or enzymatic deficits (e.g., beta-glucuronidase in mucopolysaccharidosis VII).
- coagulation factors e.g., Factor VIII in Haemophilia A
- enzymatic deficits e.g., beta-glucuronidase in mucopolysaccharidosis VII.
- mounting of immunogenic responses against the administered protein is not desirable, as this would be counterproductive for achieving the desired therapeutic effect (e.g., side effects such as cytokine release syndromes; or neutralization/degradation of the therapeutic protein).
- Another application of the method of the present invention is its use for Ag or epitope discovery (also known as“mapping”), i.e. for screening Ags and epitopes in order to select those eliciting an Ag-specific T cell response.
- Ag or epitope discovery also known as“mapping”
- kits for carrying out the methods of the present invention include the population of AAPC of the present invention and materials useful such as a device (e.g. a 96-well plate in which the AAPCs and the T cells are cocultured). Different combinations of such materials may be organized as a kit in order to aid the skilled artisan in carrying out the methods of the present invention.
- a device e.g. a 96-well plate in which the AAPCs and the T cells are cocultured.
- Different combinations of such materials may be organized as a kit in order to aid the skilled artisan in carrying out the methods of the present invention.
- FIGURES are a diagrammatic representation of FIGURES.
- Figure 1 Phenotype of the AAPC DR1 cell lines. Expression of transduced molecules: the eight Ag-encoding AAPC DR1 cell lines and the AAPC DR1 cell line were stained with anti-human CD54, CD58, CD80 and HLA-DR antibodies. Fluorescence black histograms show the expression levels of transduced molecules. The white histograms represent isotype controls (A). Expression of mouse MHC-II molecules: mouse splenocytes, NIH/3T3 cells and the AAPC DR1 cell line were stained with an anti-mouse I-A/I-E antibody.
- Fluorescence black histograms show the expression levels of mouse“classical” MHC-II molecules (I-A/I-E; H-2A, H-2E).
- the white histograms represent isotype control (B).
- Figure 2 Peptide Ag presentation by the AAPC DR1 cell lines.
- AAPC DR1 or B-EBV DR1 cell lines loaded with HA or control peptide (A), HA peptide-encoding AAPC DR1 cell lines (B) or HA protein-encoding AAPC DR1 cell lines were used to stimulate the HA-specific CD4+ T- cell clone (C).
- FIG. 3 Priming of CD4+ TLs by the AAPC DR1 cell lines or by autologous PBMCs.
- the AAPC dr1 cell lines expressing HA peptide in the ER or HA protein at the plasma membrane, or the AAPC DR1 cell line loaded with 10 pg/ml of HA peptide were used to stimulate purified CD4+ TLs for 14 days.
- autologous PBMCs were cultured with 10 pg/ml of HA peptide for the same duration. Frequency of HA-specific CD4+ effector TLs was evaluated by DR1-HA (or control DR1-CLIP) tetramer staining at day 14.
- Results show percentages of HA-tetramer+ cells among CD4+ TLs.
- a representative experiment is shown from four independent experiments with four donors (A)
- intracellular IFN-g staining was also performed after reactivation by the B-EBV DR1 cell line loaded with 10 pg/ml of HA or control peptide.
- Results show percentages of IFN-y+ cells among CD4+ TLs.
- a representative experiment is shown from six independent experiments with six donors (B).
- FIG. 4 Re-stimulation of CD4+ TLs by the AAPC DR1 cell lines or by autologous PBMCs.
- TLs generated after primary culture of autologous PBMCs loaded with lOpg/ml of HA peptide for 14 days were re-stimulated for 7 additional days by the AAPC DR1 cell lines expressing HA peptide in the ER or HA protein at the plasma membrane, or by the AAPC DR1 cell line or autologous PBMCs loaded with 10 pg/ml of HA peptide.
- Frequency of HA-specific CD4+ effector TLs was evaluated by DR1-HA (or control DR1-CLIP) tetramer staining at day 21.
- Results show percentages of HA-tetramer+ cells among CD4+ TLs.
- the naive/memory phenotype of the generated CD4+ TLs was harvested by flow cytometry using the following antibodies: anti-human CD45RO, CD45RA, CD62L and CCR7.
- Results show percentages of cells subsets among CD4+ HA-tetramer+ TLs (A).
- a representative experiment is shown from four independent experiments with four donors (B). They were also evaluated by intracellular IFN-g staining.
- a representative experiment is shown from six independent experiments with six donors (C).*P ⁇ 0.05 (repeated measures of one-way ANOVA analysis followed by Dunnett’s post test); ns, not significant.
- HA protein addressing strategies were developed to target the plasma membrane, the cytoplasm, endosomes, and the extracellular media. Excepted for the native HA protein which is addressed to the plasma membrane, the others approaches are based on the use of the extracellular domain of HA, coupling or not, to a specific signal peptide to reach the targeted cell compartment (A).
- HA peptide addressing strategies were developed to target the cytoplasm, the ER, endosomes and the extracellular media. HA peptide is coupling, or not, to a specific signal peptide to reach the targeted cell compartment (B).
- TM Transmembrane domain
- Vtg Vitellogenin.
- HLA-DRB 1*01 :01 + HLA-DRl
- HLA-DRl HLA-DRl
- PBMCs were isolated by density gradient centrifugation on lymphocyte separation medium (Eurobio, Courtaboeuf, France).
- CD4 + TLs were isolated from PBMCs by negative magnetic purification, using the Dynabead Untouched Human CD4 T Cells Kit (ThermoFischer Scientific, Illkirch, France), according to the manufacturer’s protocol.
- the viral Ag of hemagglutinin used in this study is a transmembrane protein of 566 amino acids. It is consisted of a signal peptide (HAi- ⁇ d ), an extracellular domain (HA 17-530 ) which contains the epitope HA 306-318 restricted to the HLA-DRl context, a transmembrane domain (HA 531-551 ) and by a cytoplasmic domain (HA 552-566 ).
- HAi- ⁇ d signal peptide
- HA 17-530 extracellular domain
- HA 531-551 transmembrane domain
- HA 552-566 transmembrane domain
- the signal peptide, transmembrane and cytoplasmic domains of the protein were deleted to ameliorate Ag trafficking.
- the HA protein can be express in the cytoplasm.
- the extracellular domain of HA protein was coupled to the signal peptide of the glycoprotein 75 (gp75) via a linker to target endosomes, or to the secretion signal peptide of the vitellogenin (Vtg) in order to induce secretion of the protein.
- the HA 306-3 i s peptide was used to target the cytoplasm, endosomes and the extracellular media (Figure 5B).
- HA306-318 peptide was coupled to the CD8a signal peptide, as we previously described. 21
- SEQ ID NO: 3 (Membrane HA protein (Membr HA prot)
- cDNAs Ag-encoding complementary DNAs
- GeneArt ® GeneArt ® (ThermoFischer Scientific). These cDNAs were optimized for Ag translation in mus musculus organism to favor their expression in NIH/3T3 based AAPCs. The construction of NIH/3T3 -derived AAPC DR1 was previously described. 14 The cDNAs encoding addressed Ags were subcloned into dicistronic gammaretrovirus-derived SFG vectors expressing puromycin- N-acetyltransferase. All constructs were verified by Sanger DNA sequencing. H29/293 GPG packaging cells were transfected with each vector, using the calcium chloride precipitation method.
- AAPC DR1 were genetically modified by sequential infections with cell-free gammaretroviral supernatants corresponding to the Ag of interest (Ag-encoding AAPC DR1 ), in the presence of 8pg/ml of polybrene (Sigma-Aldrich, Saint-Quentin Fallavier, France) for 16 h. Cells transduced by dicistronic vector were selected with 5pg/ml of puromycin (Sigma- Aldrich). AAPC dr1 cell lines were cultured in DMEM (ThermoFischer Scientific) supplemented with 10% of decomplemented AB human serum (Sigma-Aldrich).
- RNAs of AAPC DR1 and mouse splenocytes were extracted from 5.10 6 cells using the NucleoSpin RNA isolation kit (Macherey-Nagel, Easton, PA, USA) according to the manufacturer’s protocol.
- cDNAs were generated from200 ng of total using oligo (dT) and random sequence primers (Random Hexamer) and VersoTM cDNA kit (Thermo Fischer Scientific), according to the manufacturer's instructions.
- cDNAs were PCR-amplified obtained using primers (Eurogentec SA, vide, Belgium).
- CD4 + T-cell clone Flu-2 specific for HA306-318 peptide, was kindly provided by Pr A Godkin (Institute of Infection and Immunity, Cambridge, UK). 23 The homozygous ULA-DR1 + B- EBV cell line was a kind gift from Dr H Vie (Inserm UMR 1232, France, France).
- Culture of the T-cell clone was performed in 96-well U bottom plates in RPMI (ThermoFischer Scientific), supplemented with 1% of Fetal Calf Serum (FCS, ThermoFischer Scientific), 2 mM of glutamine (ThermoFischer Scientific), 50 IU/ml of penicillin (ThermoFischer Scientific) and 50 pg/ml of streptomycin (ThermoFischer Scientific). Culture of HLA-DRU B-EBV cell line was performed in RPMI supplemented with 10% of FCS (Fetal Calf Serum, ThermoFischer Scientific).
- AAPC dr1 were stained for 20-30 min at 4°C in phosphate-buffered saline/bovine serum albumin/ethylenediamine tetraacetic acid (PBS/BSA/EDTA) buffer with the following antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-mouse I-A/I-E (BioLegend, London, UK), FITC-conjugated anti-human CD58 (BD Biosciences, Piscataway, NJ, USA) and FITC-conjugated anti-human CD54, CD80 and HLA-DR (all from ThermoFischer Scientific).
- FITC fluorescein isothiocyanate
- CD58 BD Biosciences, Piscataway, NJ, USA
- FITC-conjugated anti-human CD54, CD80 and HLA-DR all from ThermoFischer Scientific.
- TLs were stained with the following antibodies: FITC-conjugated anti human CD4, phycoerythrin (PE)/Cyanine 7 (Cy7)-conjugated anti-human CD45RA, peridinin chlorophyll protein complex (PerCP)/Cyanine 5.5 (Cy5.5)-conjugated anti-human CD45RO, allophycocyanin (APC)-conjugated anti-human CCR7, APC/Cy7-conjugated anti-human CD62L, PerCP/Cy5.5 -conjugated anti-human PD-1 (all from ThermoFischer Scientific), APC/Cy7-conjugated anti-human CD3, brilliant violet (BV)786-conjugated anti-human CD8, APC-conjugated anti-human CTLA-4, BV711 -conjugated anti-human TIM-3 (all from Sony Biotechnology, Weybridge, UK) and BV421 -conjugated anti-
- CTLA-4 expression was also detected by intracellular staining as described below. Frequency of HA-specific CD4 + TLs was assessed by tetramer staining for 30 min at room temperature with PE-conjugated ULADRB1 *01 :01-HA (DR1-HA, Prolmmune, Oxford, UK) or control HLA-DRB 1*01 :01 -CLIP tetramers (DRl-CLIP, a kind gift of the NIH Tetramer Core Facility, Atlanta, GA, USA). Cells were analyzed using BD LSRFortessa cytometer (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA).
- TLs were treated using the Intraprep Permeabilization Reagent kit (Beckman Coulter, Villepinte, France) according to the manufacturer’s protocol. TLs were stained with the following antibodies: APC-conjugated anti- human IFN-g, PE-conjugated anti-human TNF-a, PE-conjugated anti-human granzyme B (all from ThermoFischer Scientific) and APC-conjugated anti-human perforin (Sony Biotechnology).
- CD4 + T-cell clone (10 5 per well) was cultured for 6 h with AAPC DR1 or B-EBV DR1 cell lines (10 5 per well for an APC : TL ratio of 1 : 1) previously loaded for 1 hour with 10 pg/ml of HA or MBP control peptide or cultured with Ag-encoding AAPC dr1 cell lines (10 5 per well for an APC : TL ratio of 1 : 1).
- Brefeldin A at 10 pg/ml (Sigma- Aldrich) was added for the last 5 h of incubation before intracellular cytokine staining.
- irradiated (25 Gy) Ag-encoding AAPC DR1 cell lines or irradiated AAPC DR1 loaded for 1 hour with 10pg/ml of HA or control peptides were plated (1.5 > ⁇ 10 5 per well) 4 hours before incubation with purified CD4 + TLs from healthy subjects (lxlO 6 per well) for 14 days.
- PBMCs (2/ 10 6 per well) were incubated with 10 pg/ml of HA or control peptides for the same duration.
- effector TLs (lxlO 6 per well) generated by primary culture of PBMCs pulsed with HA peptide were incubated with either irradiated (25 Gy) adherent Ag-encoding AAPC DR1 cell lines (1.5 x l0 5 per well), or either AAPC DR1 (1.5 x l0 5 per well) or autologous PBMCs (2x l0 6 per well) loaded with 10 pg/ml of HA or control peptides for 7 days.
- Prism software (GraphPad software, La Jolla, CA, USA) was used to perform repeated measures of one-way ANOVA analysis followed by Dunnett’s post test.
- Ag-encoding AAPC DR1 express molecules required to activate human CD4+ TLs but not mouse molecules involved in MHC-II Ag presentation pathway
- AAPC dr1 were constructed by gammaretroviral transduction of mouse fibroblasts NIH/3T3 with vectors encoding HLA-DRa, HLA-DRp l *01 :01 (HLA-DRl), CD80 co stimulatory and CD54 and CD58 adhesion molecules.
- HLA-DRl HLA-DRp l *01 :01
- CD80 co stimulatory and CD54 and CD58 adhesion molecules.
- Ag-encoding AAPC DR1 cell lines AAPC DR1 were additionally transduced with different constructs expressing the HA viral Ag, in the form of a protein or a peptide, and addressing the Ag to a particular cellular compartment ( Figure 5A and 5B).
- AAPC DR1 and the eight Ag-encoding AAPC dr1 cell lines presented high expression and comparable levels of HLA-DR, CD80, CD54 and CD58 molecules (Figure 1A).
- NIH/3T3 or AAPC DR1 do not express the classical mouse MHC-II molecules (I-A and I-E) at their surface ( Figure IB) neither the mouse invariant chain nor the“non-classical” mouse MHC-II molecules (H-2M and H-20), which are all involved in the mouse MHC-II Ag presentation pathway (data not shown).
- Figure IB neither the mouse invariant chain nor the“non-classical” mouse MHC-II molecules (H-2M and H-20), which are all involved in the mouse MHC-II Ag presentation pathway (data not shown).
- AAPC DR1 loaded with HA peptide were very efficient to activate the specific T-cell clone, at a higher level than B-EBV DR1 cells (Figure 2A)
- Figure 2B and 2C those expressing HA peptide in the ER and those expressing HA protein at the plasma membrane are the most powerful stimulatory cells ( Figure 2B and 2C).
- Figure 2B and 2C these both AAPCs have similar Ag presentation ability than AAPC DR1 loaded with HA peptide.
- AAPC DR1 expressing HA Ag in the cytoplasm have the lowest stimulatory capacities.
- AAPC DR1 expressing HA peptide in the ER and HA protein at the cell surface, and evaluated their ability to prime human CD4+ T cell response.
- the two HA Ag- encoding AAPC dr1 were able to generate HA-specific CD4+ T cell with the same efficacy than AAPC dr1 pulsed with HA peptide.
- HA-tetramer staining and IFN-g production after reactivation with B-EBV DR1 cells show about 1,5 to 3% specific CD4+ T cells ( Figure 3A and 3B).
- Ag-encoding AAPC DR1 expressing HA peptide in the ER are more effective to reactivate memory specific CD4+ T cell than autologous APCs
- HA-specific CD4+ TLs were IFN-g and TNF-a producing Thl cells with a similar naif/memory phenotype including a majority of effector memory T cells (TEM; CD45RO + , CD62L , CCR7 ) ( Figure 4A and 40.
- the other cells were transitional memory (TTM; CD45RO + , CD62L + , CCR7 ).
- TTM transitional memory
- a contingent of CD4+ T cells produce granzyme B but not perforin after reactivation with the HA peptide, suggesting they are cytotoxic T cells (data not shown).
- Re-stimulation by autologous APCs or AAPCs increased similarly expression of immuno-regulation molecules as T cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin and mucin- domain containing-3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1 (data not shown).
- TAGIT T cell immunoreceptor with Ig and ITIM domains
- TIM-3 T-cell immunoglobulin and mucin- domain containing-3
- CTLA-4 cytotoxic T lymphocyte antigen-4
- PD-1 data not shown.
- the high efficiency of peptide encoding AAPC dr1 in ER may explain by an optimal loading of HA peptide into nascent MHC-II molecule in absence of the chaperone protein Ii that blocks peptide cleft.
- the potent Ag presentation ability of AAPC DR1 expressing HA protein at the cell membrane may result of the recycling of HA proteins and HLA-DR1 molecules. Indeed, it has been already demonstrated in professional APCs but also in fibroblasts that some HA epitopes can be generated into early endosomes which contain MHC-II recycled molecules and unfolding HA protein that have underwent mild proteolysis, independently of Ii and HLA-DM present in the MIIC.
- AAPCs expressing peptide or protein in extracellular media were less efficient to present Ag than AAPCs targeting ER or the plasma membrane likely because of a low level of endocytosis.
- AAPCs expressing HA protein or peptide in the cytosol are the weakest stimulating cells.
- AAPCs expressing HA peptide in ER or protein in membrane as well as AAPCs loaded with HA peptide have strong Ag presentation capacity, they activate effector CD4+ T cells after primary stimulation but at lower level than autologous APCs. It is likely that endogenous expression of HA Ag is not sufficient to hamper presentation of xenopeptide competitors and so to limit non-specific CD4+ T cell responses.
- a promising approach is to induce expression of the TAP inhibitors such as UL49.5 and US6 viral proteins of AAPC DR1 by gene transfer. 30
- the xenopeptides presented by HLA-DR1 molecules can also arise from autophagy mechanisms.
- CD4+ T cells express immuno-regulation molecules as TIGIT, TIM-3, PD-1 and CTLA-4 that could limit their functionality in vivo. It was shown that CTL based ACI efficiency was improved by immune checkpoints blockades combination. 37,38 It likely that the same therapeutic approach is required for ACI replying in part on effector CD4+ T cells. AAPCs could also be modified to express appropriate costimulation signals that improve CD4+ TLs survival and functionality. For this purpose, CD70 and 4-1BBL molecules are two promising candidates. Indeed, the CD27/CD70 costimulatory signaling pathway has been reported to promotes Thl polarization but also CD4+ TLs survival.
- Sadegh-Nasseri S A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. FlOOOResearch 2016; 5.
- Lam TH Mamitsuka H, Ren EC, Tong JC.
- TAP Hunter a SVM-based system for predicting TAP ligands using local description of amino acid sequence. Immunome Res 2010; 6 Suppl 1: S6
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy. To induce CD4+ T cell responses, the inventors have developed artificial antigen presenting cells (AAPCs) that derived from a mouse fibroblast cell line genetically modified to express a single human leukocyte antigen class II molecule (HLA-DR), the human CD80 costimulation as well as CD54 and CD58 adhesion molecules and that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway. In particular, the inventors show that the AAPC expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein-Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T- cells. Interestingly, AAPC targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPC or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Th1 profile and express granzyme B. So, the AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy. Thus, the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
Description
ARTIFICIAL ANTIGEN PRESENTING CELLS THAT CONSTITUTIVELY EXPRESS AN ANTIGEN ALONG WITH A HLA-CLASS II MOLECULE
FIELD OF THE INVENTION:
The present invention is in the field of immunology. In particular, the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
BACKGROUND OF THE INVENTION:
Adoptive cell immunotherapy (ACI) strategies, using human functional Ag-specific T lymphocytes (TLs), represent an emerging therapeutic approach to treat cancer but also chronic viral infections. Even if cytotoxic CD8+ TLs (CTLs) are the main effectors of the anti-tumor immune response, CD4+ helper T cells (Th) are crucial to support indirectly the CD8+ responses.1 CD40 signaling on dendritic cells (DCs) via an interaction with activated Th cells expressing CD40-L increased Ag presentation and costimulatory capacity of DCs and promote efficient CTL priming.2 IL-2 secretion by Th cells and induction of IL-15 production by DCs is critical for memory CTL responses.3,4 Recently, it was shown that CD4+ T cells up-regulated CD70 on DCs which in turn interact with CD27 on CTLs delivering a help program that amplify CTL responses and down-regulated exhaustion molecules such as Programmed Death- 1 (PD- l).5 In addition, CD4+ TLs can act directly against tumor cells without contribution of CD8+ T cells. CD4+ T cells including Thl, Th9 and Thl7 can act directly against tumor by secreting effector cytokines and/or displaying cytotoxic activity against major histocompatibility complex class II (MHC-II) positive tumors.6-8
The use of CD4+ TLs in preliminary clinical trials of ACI has shown promising results. Infusion of in vitro expanded autologous CD4+ T-cell clones specific for the New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) Ag led to durable remission in a patient with metastatic melanoma.9 Moreover, MHC-II-restricted neoantigens were found in many cancers and represent interesting targets for clinical applications.10-12 A disease stabilization was observed in a patient with metastatic cholangio sarcoma after ACI with Thl tumor infiltrating lymphocytes (TILs) specific for a neoantigen deriving from the erbb2 interacting protein (ERBB2IP).13
However, the main limiting step for an effective ACI is the generation of a sufficient number of Ag-specific TLs by antigen presenting cells (APCs). In vitro , preparation of such
APCs, like DCs, is time consuming and can raises concerns about their quantity, maintenance of their phenotype and functionality. To bypass these difficulties, our group has developed artificial antigen presenting cells (AAPCs) derived from mouse fibroblast NIH/3T3 and expressing a single human leukocyte antigen class II (HLA-II) molecule (HLA-DR1), the co stimulatory molecule CD80 (B7.1) and the two adhesion molecules CD54 (intercellular adhesion molecule-1, ICAM-1) and CD58 (lymphocyte function-associated antigen-3, LFA- 3).14 We have shown that these AAPCs (named AAPCDR) have strong abilities to present exogenous peptide or epitope from whole Ag that have been uptaken. AAPCDR exhibit lower ability to prime specific CD4+ T cells than autologous peripheral blood mononuclear cells (PBMCs), but had better ability to re-stimulate functional memory Ag-specific Thl cells than autologous APCs.
To optimize and standardize AAPCDR model, induction of endogenous and constitutive expression of the Ag could be an interesting approach. Nevertheless, the cell compartments to target for Ag expression should be accurately investigated. In the classical MHC-II Ag presentation pathway, MHC-II molecules a and b chains are assembled within the endoplasmic reticulum (ER) and associated with the invariant chain (Ii). This heterotrimer migrate, via the Golgi apparatus, to the MHC-II compartment (MIIC). In this specialized endolysosomal compartment, Ii is sequentially degraded by proteases and only the class II invariant chain peptide (CLIP) remains in the MHC-II molecule groove. CLIP peptides are then replaced by peptides of higher affinity due to the HLA-DM chaperone protein. These peptides are mainly originated from exogenous Ags that are endocytosed by APCs and degraded by proteases but could arise from endogenous peptide from autophagosomes. Then, peptide/MHC-II complexes will migrate to the APC plasma membrane.15-17
SUMMARY OF THE INVENTION:
As defined by the claims, the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
DETAILED DESCRIPTION OF THE INVENTION:
CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy. To induce CD4+ T cell responses, the inventors have previously developed artificial antigen presenting cells (AAPCs) that derived from a mouse fibroblast cell line genetically modified to express a single human leukocyte antigen class II molecule (HLA-DR), the human CD80 costimulation as well as CD54 and
CD58 adhesion molecules. In this study, the model was optimized with novel AAPCs HLA- DR1+ (AAPCdr1) that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway. The inventors found that AAPCDR1 expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein- Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T-cells. In addition, these two Ag-encoding AAPC cell lines prime specific CD4+ T cells but at lower level than autologous peripheral blood mononuclear cells (PBMCs) used as CPA. Interestingly, AAPCDR1 targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPCDR1 or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Thl profile and express granzyme B. So, our AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy.
A) Artificial antisen presenting cells of the present invention:
Thus the first object of the present invention relates to an artificial antigen presenting cell consisting of a eucaryotic cell that is genetically modified to stably express a single MHC class II molecule, at least one accessory molecule and at least one antigen.
As used herein, the term "antigen-presenting cell" or "APC" refers to a class of cells capable of presenting antigen to T lymphocytes which recognize antigen when it is associated with a major histocompatibility complex molecule. APCs elicit a T cell response to a specific antigen by processing the antigen into a form that is capable of associating with a major histocompatibility complex molecule on the surface of the APC.
As used herein, an "artificial antigen presenting cell” or“AAPC” refers to a eucaryotic cell that has been genetically engineered to function as a professional APC for one or more selected antigens.
According to the present invention, the eucaryotic cell does not express naturally MHC molecules and in particular class II molecules. In some embodiments, the eucaryotic cell is naturally deficient for the expression of a MHC molecule. In some embodiments, the eucaryotic cell was previously genetically modified so as to not express a MHC molecule (e.g. by using CRISPR-cas9). In some embodiments, the eucaryotic cell is naturally deficient for the expression of a molecule that is involved in the formation and transport of the MHC class II molecules. In some embodiments, the eucaryotic cell was previously genetically modified so as to not express molecule that is involved in the formation and transport of the MHC class II
molecules. Typically, the molecule that is involved in the formation and transport of the MHC class II molecules is the invariant molecule also named as“li” or“CD74”.
In some embodiments, the eucaryotic cell is not a cell deriving from the hematopoietic lineage and can be human, murine, rodentia, insect, or any other mammalian cells. When the artificial antigen presenting cell is used for activation and/or amplifying human specific CD4+ T cells, the eucaryotic cell is preferably selected from a different species. In some embodiments, the eucaryotic cell is preferably a murine cell. In some embodiments, the cells are fibroblasts, and more particularly murine fibroblast (e.g. NIH/3T3 mouse fibroblasts).
As used herein, the term "MHC Class II" or "Class II" refers to the human Major Histocompatibility Complex Class II proteins, binding peptides or genes. The human MHC region, also referred to as HLA, is found on chromosome six and includes the Class I region and the Class II region. Within the MHC Class II region are found the DP, DQ and DR subregions for Class II a chain and b chain genes (i.e., DPa, ϋRb, DQa, DC , DRa, and DRb).
As used herein, the term "MHC Class II molecule" means a covalently or non-covalently joined complex of an MHC Class II a chain and an MHC Class II b chain. MHC class II molecules bind peptides in an intracellular processing compartment and present these peptides on the surface of antigen presenting cells to T cells. As used herein, the term "MHC Class II a chain" means a naturally occurring polypeptide, or one encoded by an artificially mutated a gene, essentially corresponding to at least the al and a2 extracellular domains of one of the gene products of an MHC Class II a gene. As the C-terminal transmembrane and cytoplasmic portions of the a chain are not necessary for antigenic peptide binding in the present invention, they may be omitted while retaining biological activity. As used herein, the term "MHC Class II b chain" means a naturally occurring polypeptide, or one encoded by an artificially mutated b gene, essentially corresponding to at least the bΐ and b2 extracellular domain of one of the gene products of an MHC Class II b. As the C- terminal transmembrane and cytoplasmic portions of the b chain are not necessary for antigenic peptide binding in the present invention, they may be omitted while retaining biological activity.
In some embodiments, the MHC class II molecule is selected from the group consisting of HLA-DQ molecules, HLA-DP molecules and HLA-DR molecules. In some embodiments, the MHC class II molecule is selected from the group consisting of HLA-DRl, HLA-DR15 and HLA-DR51 molecules.
In some embodiments, the at least one accessory molecule is selected from the group consisting of co-stimulatory molecules and adhesion molecules.
The term“co-stimulatory molecule” is used herein in accordance with its art recognized meaning in immune T cell activation. Specifically, a“co-stimulatory molecule” refers to a group of immune cell surface receptor/ligands which engage between T cells and antigen presenting cells and generate a stimulatory signal in T cells which combines with the stimulatory signal (i.e.,“co-stimulation”) in T cells that results from T cell receptor (“TCR”) recognition of antigen on antigen presenting cells.
In some embodiments, the co-stimulatory molecule is CD80. As used herein the term “CD80” has its general meaning in the art and refers to B7-1 molecule which is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (T cell activation and survival) and CTLA-4 (T cell inhibition) (Peach, R J; Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley P S (Sep 1995). "Both extracellular immunoglobin- like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28". J. Biol. Chem. (UNITED STATES) 270 (36): 21181-7; Stamper, C C; Zhang Y, Tobin J F, Erbe D V, Ikemizu S, Davis S J, Stahl M L, Seehra J, Somers W S, Mosyak L (Mar 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature (England) 410 (6828): 608-11).
As used herein, the term "adhesion molecule" refers to a molecule on the surface of a cell whose primary, or predominant, function is to increase the strength or avidity of the interaction of the cell with another cell (e.g., the interaction between a T cell and an artificial antigen presenting cell of the present invention). Examples of families of adhesion molecules include integrins and selectins.
In some embodiment, the adhesion molecule is CD54. As used herein the term“CD54” has its general meaning in the art and refers to ICAM-1 (Intercellular Adhesion Molecule 1) also known as CD54 (Cluster of Differentiation 54) (Carlson M, Nakamura Y, Payson R, O'Connell P, Leppert M, Lathrop GM, Lalouel JM, White R (May 1988). "Isolation and mapping of a polymorphic DNA sequence (pMCT108.2) on chromosome 18 D18S24". Nucleic Acids Res. 16 (9): 4188.; Katz FE, Parkar M, Stanley K, Murray LJ, Clark EA, Greaves MF (January 1985). "Chromosome mapping of cell membrane antigens expressed on activated B cells". Eur. J. Immunol. 15 (1): 103-6). ICAM-1 is a member of the immunoglobulin superfamily, the superfamily of proteins including antibodies and T-cell receptors. ICAM-1 is a transmembrane protein possessing an amino-terminus extracellular domain, a single transmembrane domain, and a carboxy-terminus cytoplasmic domain. The structure of ICAM-
1 is characterized by heavy glycosylation, and the protein’s extracellular domain is composed of multiple loops created by disulfide bridges within the protein.
In some embodiment, the adhesion molecule is CD58. As used herein the term“CD58” has its general meaning in the art and refers to lymphocyte function-associated antigen 3 (LFA- 3) which is a cell adhesion molecule expressed on Antigen Presenting Cells (APC), particularly macrophages (Barbosa JA, Mentzer S J, Kamarck ME, Hart J, Biro PA, Strominger JL, Burakoff SJ (April 1986). "Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions". J. Immunol. 136 (8): 3085-91.; Wallich R, Brenner C, Brand Y, Roux M, Reister M, Meuer S (15 March 1998). "Gene structure, promoter characterization, and basis for alternative mRNA splicing of the human CD58 gene". J. Immunol. 160 (6): 2862-71).
In some embodiments, the eucaryotic cell is genetically modified to stably express the CD80, CD54 and CD58 molecules.
As used herein, the term“antigen” (“Ag”) refers to a whole protein or peptide capable of eliciting a T-cell response. The skilled person in the art will be able to select the appropriate antigen, depending on the desired T-cell stimulation.
In some embodiments, the eucaryotic cell is genetically modified to stably express the antigen in a particular compartment of the cell. In some embodiments, when the antigen is peptide, it is particularly advantageous to express said peptide is in the endoplasmic reticulum (ER). In some embodiments, when the antigen is a protein it is particularly advantageous to express said protein in the endosomes or in the membrane (e.g. a transmembrane protein). Thus the skilled person will thus select the antigen with the appropriate way of expression.
As used herein, the term "endoplasmic reticulum" or "ER" has its general meaning in the art and refers to a eukaryotic cell organelle that forms an interconnected network of tubules, vesicles, and cisternae within cells that is involved in the production of phospholipids and proteins, among other functions. The ER facilitates proper protein folding and quality control (QC) for protein processing. During translation, proteins are translocated into the ER lumen after recognition of the signal sequence.
As used herein, the term“endosome” has its general meaning in the art and refers to a membrane-bound compartment inside eukaryotic cells. It is a compartment of the endocytic membrane transport pathway originating from the trans Golgi membrane.
As used herein, the term“signal peptide” or“leader sequence” has its general meaning in the art and refers to a short amino acid sequence that directs a newly synthesized protein through the endoplasmic reticulum, golgi or endosomes. The signal peptide is a short peptide,
commonly 5-30 amino acids long, present at the N- terminus of the majority of newly synthesized proteins. Signal peptides commonly contain a core sequence which is a long stretch of hydrophobic amino acids that has a tendency to form a single alpha-helix. The signal peptide may begin with a short positively charged stretch of amino acids, which helps to enforce proper topology of the peptide during translocation. At the end of the signal peptide there is typically a stretch of amino acids that is recognized and cleaved by signal peptidase. The hydrophobic amino acids in the core may, for example be: Alanine (A); Valine (V); Isoleucine (I); Leucine (L); Methionine (M); Phenylalanine (P); Tyrosine (Y); or Tryptophan (W). Signal sequences can be detected or predicted using software techniques (see for example, http://www.predisi.de/). A very large number of signal sequences are known, and are available in databases. For example, http://www.signalpeptide.de lists 2109 confirmed mammalian signal peptides in its database.
In some embodiments, the signal peptide is the signal peptide of the T cell surface glycoprotein CD8 alpha chain. In particular, use of said signal peptide is particularly advantageous for expressing a peptide in the endoplasmic reticulum. In some embodiments, the signal peptide has the amino acid sequence as forth in SEQ ID NO: 1.
SEQ ID NO: 1
MALPVTALLLPLALLLHASQA
Accordingly, in some embodiments, the eucaryotic cell is genetically modified to stably express the antigen (e.g. peptide) fused to the signal sequence. In some embodiments, the antigen (e.g. peptide) is fused directly at its N-terminal end to the signal sequence. As used herein, the term“directly” means that the first amino acid at the N-terminal end of the antigen (e.g. peptide) is fused to the last amino acid at the C-terminal end of the signal peptide.
According to the present invention when the antigen is a protein, the eucaryotic cell is genetically modified to stably express a protein (i.e. the antigen) at the plasma membrane.
As used herein, the term“plasma membrane” means the phospholipid bilayer structure that comprises the external boundary of a cell. Plasma membranes have an external or extracellular face and an internal or intracellular face. Each face has unique features and components (i.e. proteins) associated with it that give it its unique properties. In addition, adherent cells exhibit polarity, meaning the aspect of the cell that is attached to the basement membrane, called the basal face, has different features than the aspect of the cell that is adluminal, called the apical face.
In some embodiments, the protein comprises a domain that will anchored the protein to the plasma membrane. In some embodiments, the protein comprises a transmembrane domain, i.e. a protein domain which traverses the cell membrane.
In some embodiments, the protein is a transmembrane protein. As used herein, the term "transmembrane protein" is a type of membrane protein spanning the entirety of the plasma membrane to which it is permanently attached in nature. That is, in nature, transmembrane proteins span from one side of a membrane through to the other side of the membrane.
In some embodiments, the antigen is a viral antigen. Examples of viral antigens include but are not limited to influenza viral Antigens (e.g. hemagglutinin (HA) protein, matrix 2 (M2) protein, neuraminidase), respiratory syncitial virus (RSV) Antigens (e.g. fusion protein, attachment glycoprotein), polio, papillomaviral (e.g. human papilloma virus (HPV), such as an E6 protein, E7 protein, LI protein and L2 protein), Herpes simplex, rabies virus and flavivirus viral Ags (e.g. Dengue viral Ags, West Nile viral Ags), hepatitis viral Ags including Ags from HBV and HCV, human immunodeficiency virus (HIV) Ags (e.g. gag, pol or nef), herpesvirus (such as cytomegalovirus and Epstein-Barr virus) Ags (e.g. pp65, IE1, EBNA-1, BZLF-1) and adenovirus Ags.
In some embodiments, the antigen is a bacterial antigen. Examples of bacterial Ags include but are not limited to those from Streptococcus pneumonia, Haemophilus influenza, Staphylococcus aureus, Clostridium difficile and enteric gram-negative pathogens including Escherichia, Salmonella, Shigella, Yersinia, Klebsiella, Pseudomonas, Enterobacter, Serratia, Proteus, B. anthracis, C. tetani, B. pertussis, S. pyogenes, S. aureus, N meningitidis and Haemophilus influenzae type b.
In some embodiments, the antigen is a fungal or protozoal antigen. Examples include but are not limited to those from Candida spp., Aspergillus spp., Crytococcus neoformans, Coccidiodes spp., Histoplasma capsulatum, Pneumocystis carinii, Paracoccidiodes brasiliensis, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale , and Plasmodium malar iae.
In some embodiments, the antigen is a tumor-associated Antigen (TAA). Examples of TAAs include, without limitation, melanoma-associated Ags (Melan-A/MART-1, MAGE-1, MAGE-3, TRP-2, melanosomal membrane glycoprotein gplOO, gp75 and MUC-1 (mucin-1) associated with melanoma); CEA (carcinoembryonic Antigen) which can be associated, e.g., with ovarian, melanoma or colon cancers; folate receptor alpha expressed by ovarian carcinoma; free human chorionic gonadotropin beta (hCGP) subunit expressed by many different tumors, including but not limited to ovarian tumors, testicular tumors and myeloma;
HER-2/neu associated with breast cancer; NY-ESO-1 of metastatic carcinomas, encephalomyelitis antigen HuD associated with small-cell lung cancer; tyrosine hydroxylase associated with neuroblastoma; prostate-specific antigen (PSA) associated with prostate cancer; CA125 associated with ovarian cancer; and the idiotypic determinants of a B-cell lymphoma that can generate tumor-specific immunity (attributed to idiotype-specific humoral immune response). Moreover, Ags of human T cell leukemia virus type 1 have been shown to induce specific cytotoxic T cell responses and anti-tumor immunity against the virus-induced human adult T-cell leukemia (ATL).
In some embodiments, the antigen is an auto-antigen. As used herein, the term“auto- antigen” means any self-antigen arising from the own body tissues which is mistakenly recognized by the immune system as being foreign. Auto-antigens comprise, but are not limited to, cellular proteins, phosphoproteins, cellular surface proteins, cellular lipids, nucleic acids, glycoproteins, including cell surface receptors. Examples of auto-antigens include but are not limited to preproinsulin (PPI), glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 (IA-2), islet-specific glucose-6-phosphatase catalytic-subunit-related protein (IGRP), zinc transporter 8 (ZnT8) and chromogranin A for T1D; myeloperoxydase and proteinase 3 for granulomatosis with polyangiitis; myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in multiple sclerosis; and gliadins in celiac disease
In some embodiments, the antigen is an allergen. As used herein, the term“allergen” generally refers to an antigen or antigenic portion of a molecule, usually a protein, which elicits an allergic response upon exposure to a subject. Typically the subject is allergic to the allergen as indicated, for instance, by the wheal and flare test or any method known in the art. A molecule is said to be an allergen even if only a small subset of subjects exhibit an allergic immune response upon exposure to the molecule.
The AAPC of the present invention may be prepared according to any well-known method in the art. For general guidance regarding the preparation of artificial antigen-presenting cells according to the invention, the skilled would refer to the international patent application WO 2001094944; Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigenpresenting cells. Nat Biotechnol 2000; 18:405-9. Briefly, the AAPCs of the present are typically produced ex vivo by the insertion of one or more recombinant or synthetic nucleic acid sequences (genes) encoding the molecules of interest, such that the molecules are expressed in effective amounts in the recipient subject cell. Accordingly, genetic modification of the eucaryotic cell can be accomplished at any point during their maintenance by transducing a substantially homogeneous cell composition with a recombinant DNA construct. The nucleic
acid sequences can be obtained by conventional methods well known to those skilled in the art. Typically, said nucleic acid is a DNA or RNA molecule. Useful nucleic acid molecules for constructing the AAPCs of the present invention (e.g., selected antigens, MHC molecules, adhesion molecules, costimulatory molecules, etc.) are cloned into a vector before they are introduced into the eucaryotic cell and optionally are passage in cells other than AAPCs to generate useable quantities of these nucleic acids. As used herein, the terms "vector", "cloning vector" and "expression vector" mean the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a eucaryotic cell, so as to transform the cell and promote expression (e.g. transcription and translation) of the introduced sequence. Suitable vectors for the invention may be plasmid or viral vectors, including baculoviruses, adenoviruses, poxviruses, adenoassociated viruses (AAV), and retrovirus vectors (Price et al, 1987, Proc. Natl. Acad. Sci. USA, 84: 156-160) such as the MMLV based replication incompetent vector pMV-7 (Kirschmeier et al., 1988, DNA, 7:219-225), as well as human and yeast modified chromosomes (HACs and YACs). Plasmid expression vectors include plasmids including pBR322, pUC or Bluescript.TM. (Stratagene, San Diego, Calif). Typically retroviral vectors are used for introducing the nucleic acid of interest into the eucaryotic cell. The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse- transcription (Coffin, 1990, in Fields et al., Ceds, Virology, Raven Press, New York, pp. 1437- 1500). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the eucaryotic cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene, functions as a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the subject cell genome (Coffin, supra). Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, 1990, Blood 76:271). Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.), 1989, Greene Publishing Associates, Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus cell lines include Crip, Cre, 2 and Am. Retroviruses have been used to introduce a variety of genes into many different cell types,
including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al., 1985, Science, 230: 1395- 1398; Danos, et al., 1988, Proc. Natl. Acad. Sci. USA, 85:6460-6464; Wilson et al., 1988, Proc. Natl. Acad. Sci. USA, 85:3014-3018; Armentano et al., 1990, Proc. Natl. Acad. Sci. USA, 87:6141- 6145; Huber et al, 1991, Proc. Natl. Acad. Sci. USA, 88:8039-8043; Ferry et al., 1991, Proc. Natl. Acad. Sci. USA, 88:8377-8381; Chowdhury et al., 1991, Science, 254: 1802-1805; van Beusechem et al, 1992, Proc. Natl. Acad. Sci. USA, 89:7640-7644; Kay et al, 1992, Human Gene Therapy, 3 :641-647; Dai et al., 1992, Proc. Natl. Acad. Sci. USA, 89: 10892-10895; Hwu et al., 1993, J. Immunol., 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573). Retroviral vectors require target cell division in order for the retroviral genome (and foreign nucleic acid inserted into it) to be integrated into the subject genome to stably introduce nucleic acid into the cell. Thus, it may be necessary to stimulate replication of the target cell. In some embodiments, gamma-retroviral vector is used (Tobias Maetzig, Melanie Galla, Christopher Baum, and Axel Schambach Gammaretroviral Vectors: Biology, Technology and Application. Viruses. Jun 2011; 3(6): 677- 713.). In particular a Gamma-retrovirus-derived SFG vector as described in EXAMPLE is used.
In some embodiments, a plurality of vectors are employed, each vector encoding one molecule of interest (i.e. the MHC class II molecule, the accessory molecule or the antigen). In some embodiments, the expression of the exogenous nucleic acid is under the control of a promoter. Examples of promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40 (Mizukami T. et al. 1987), LTR promoter and enhancer of Moloney mouse leukemia virus (Kuwana Y et al. 1987), promoter (Mason JO et al. 1985) and enhancer (Gillies SD et al. 1983) of immunoglobulin chain and the like.
In some embodiments, a vector comprising a nucleic acid sequence encoding for the signal peptide operatively linked to a nucleic acid sequence encoding for the antigen (e.g. peptide) is used to stably express the antigen peptide into the endoplasmic reticulum of the eucaryotic cell. In some embodiments, the nucleic acid sequence encoding for the signal peptide consists of the nucleic acid sequence as set forth in SEQ ID NO: 2.
SEQ ID NO: 2
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCATCGCAAGCA
As used herein, the terms "operably linked", or "operatively linked" are used interchangeably herein, and refer to the functional relationship of the nucleic acid sequences
and indicates that two or more DNA segments are joined together such that they function in concert for their intended purposes.
Typically, the expression vectors comprise one or more regulatory elements to drive and/or enhance expression of upstream or downstream nucleic acids. These regulatory sequences are selected on the basis of the cells (e.g., types of AAPCs) to be used for expression, and are operatively linked to a nucleic acid sequence to be expressed. The term "regulatory elements" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory elements are described, for example, in Goeddel; 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA. Regulatory elements include those which direct expression of a nucleotide sequence in many types of subject cells as well as those which direct expression of the nucleotide sequence only in certain subject cells (e.g., tissue-specific regulatory sequences). Regulatory elements also include those which direct constitutive expression of an operatively linked nucleic acid sequence and those which direct inducible expression of the nucleic acid sequence. Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad range of cells in which they can activate and/or modulate transcription while others are functional only in a limited subset of cell types (See e.g., Voss et al, 1986, Trends Biochem. Sci., 11 :287; and Maniatis et ah, supra, for reviews). For example, the SV40 early gene enhancer is very active in a wide variety of cell types from many eucaryotic species and has been widely used for the expression of proteins in mammalian cells (Dijkema et al, 1985, EMBO J. 4:761). Two other examples of promoter/enhancer elements active in a broad range of mammalian cell types are those from the human elongation factor la gene (Uetsuki et al., 1989, J. Biol. Chem., 264:5791; Kim et al., 1990, Gene, 91 :217; and Mizushima, et al, 1990, Nagata, Nuc. Acids. Res., 18:5322) and the long terminal repeats of the Rous sarcoma virus (Gorman et al., 1982, Proc. Natl. Acad. Sci. USA, 79:6777) and the human cytomegalovirus (Boshart et al., 1985, Cell, 41 :521). Suitable promoters which may be employed include, but are not limited to, TRAP promoters, adenoviral promoters, such as the adenoviral major late promoter; the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter, heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the
Herpes Simplex thymidine kinase promoter; retroviral LTRs; ITRs; the b- actin promoter; and human growth hormone promoters. The promoter also may be the native promoter that controls the nucleic acid encoding the polypeptide and the sequences of native promoters may be found in the art (see Agrawal et al., 2000, J. Hematother. Stem Cell Res., 795- 812; Coumoyer et al., 1993, Annu. Rev. Immunol., 11 :297-329; van de Stolpe et al., 1996, J. Mol. Med., 74: 13-33; Herrmann, 1995, J. Mol. Med., 73 : 157-63). A variety of enhancer sequences can also be used in the instant invention including but not limited to: Immunoglobulin Heavy Chain enhancer; Immunoglobulin Light Chain enhancer; T- Cell Receptor enhancer; HLA DQa and DQP enhancers ; b-Interferon enhancer; interleukin-2 enhancer; Interleukin-2 Receptor enhancer;; MHC Class II HLA-DRa enhancer ; b-Actin enhancer; Muscle Creatine Kinase enhancer; Prealbumin (Transthyretin) enhancer; Elastase I enhancer; Metallothionein enhancer; Collagenase enhancer; Albumin Gene enhancer; a-Fetoprotein enhancer; b-Globin enhancer; c-fos enhancer; c-HA-ras enhancer; Insulin enhancer; Neural Cell Adhesion Molecule (NCAM) enhancer; al -Antitrypsin enhancer; H2B (TH2B) Histone enhancer; Mouse or Type I Collagen enhancer; Glucose- Regulated Proteins (GRP94 and GRP78) enhancer; Rat Growth Hormone enhancer; Human Serum Amyloid A (SAA) enhancer; Troponin I (TN I) enhancer; Platelet- Derived Growth Factor enhancer; Duchenne Muscular Dystrophy enhancer; SV40 Polyoma enhancer; Retrovirusal enhancer; Papilloma Virus enhancer; Hepatitis B Virus enhancer; Human Immunodeficiency enhancer; Cytomegalovirus enhancer; and Gibbon Ape Leukemia Virus enhancer.
The artificial antigen presenting cell of the present invention may find applications and uses in a wide number of contexts.
B) Methods of activatins and/or amplifying a population of antisen-syecific CD4+ T cells:
A further object of the present invention relates to a method of activating and/or amplifying a population of antigen-specific CD4+ T cells comprising the steps of coculturing a population of a T cells with the population of artificial antigen presenting cells of the present invention.
In some embodiments, the population of AAPCs is irradiated by any conventional method well known in the art before incubation with the population of CD4 T cells.
In some embodiments, the population of CD4+ T cells is substantially purified by magnetic bead purification systems such as those available in the art, e.g., Miltenyi beads (Myltenyi Biotec) and Dynabead systems (Dynal Biotech) or with cell sorting procedures, such as FACS-based methods, or other appropriate cell sorting devices and methodologies. In some
embodiments, the population of CD4+ T cells is purified from a PBMC sample. The term “PBMC” or“peripheral blood mononuclear cells” or“unfractionated PBMC”, as used herein, refers to whole PBMC, i.e. to a population of white blood cells having a round nucleus, which has not been enriched for a given sub-population. Cord blood mononuclear cells are further included in this definition. Typically, the PBMC sample according to the invention has not been subjected to a selection step to contain only adherent PBMC (which consist essentially of >90% monocytes) or non-adherent PBMC (which contain T cells, B cells, natural killer (NK) cells, NK T cells and DC precursors). A PBMC sample according to the invention therefore contains lymphocytes (B cells, T cells, NK cells, NKT cells), monocytes, and precursors thereof. Typically, these cells can be extracted from whole blood using Ficoll, a hydrophilic polysaccharide that separates layers of blood, with the PBMC forming a cell ring under a layer of plasma. Additionally, PBMC can be extracted from whole blood using a hypotonic lysis buffer which will preferentially lyse red blood cells.
The population of CD4+ T cells and the population of AAPC are cocultured for a time sufficient to activate and enrich for a desired population of activated memory CD4+ T cells. For instance, the T cells and the AAPCs of the present invention are contacted for 5, 6, 7, 8, 9, 10, 11, or 12, days. Typically the T cells and the AAPCs of the present invention are contacted for at least 7 days. Any culture medium suitable for growth, survival and differentiation of T cells is used for the coculturing step. Typically, it consists of a base medium containing nutrients (a source of carbon, aminoacids), a pH buffer and salts, which can be supplemented with serum of human or other origin and/or growth factors and/or antibiotics to various cytokines could be added. Typically, the base medium can be RPMI 1640, DMEM, IMDM, X- VIVO or AIM-V medium, all of which are commercially available standard media.
In particular, the method of the present invention is particularly suitable for activating and/or amplifying a population of antigen-specific memory CD4+ T cells.
As used herein the term "memory CD4+ T cell" has its general meaning in the art and to a subset of CD4+ T cells that are specific to the antigen they first encountered and can be called upon during the secondary immune response. Typically, memory CD4+ T cells are characterized by the expression at their cell surface of CD45RO.
In some embodiments, the method further comprises the step of isolating the population of antigen-specific CD4+ T cells. Methods for isolating the population of antigen-specific CD4+ T cells are conventional to the skilled person. In some embodiments, the method may use Class II multimers. With this procedure, Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g., Prolmmune MHC
Class I Pentamers, Class II Ultimers; or Immudex MHC Dextramers) or in-house generated ones, e.g., from the NIH Tetramer Facility at Emory University, USA; from Dr. S. Buus, University of Copenhagen, Denmark [Leisner et al, PLoSOne 3 :el678, 2008], from Dr. G.T. Nepom, Benaroya Research Institute, Seattle, USA [Novak et al, J.Clin.Invest. 104:R63, 1999] In some embodiments, the method is based on the detection of the upregulation of activation markers. With this procedure, Antigen-specific T helper cell responses are detected by their differential expression of activation markers exposed on the membrane following Ag- recognition. In some embodiments, the method may consist in a cytokine capture assay. This system developed by Miltenyi Biotech is a valid alternative to the ELISpot to visualize Antigen- specific T helper cells according to their cytokine response. In some embodiments, the method may consist of a CD 154 assay. This procedure has been described in detail [Chattopadhyay et al, Nat.Med. 11 : 1113, 2005; Frentsch et al., Nat.Med. 11 : 1118, 2005] It is limited to detection of Ag-specific CD4+ T cells. In some embodiments, the method may consist in a CFSE dilution assay. This procedure detects Antigen-specific T helper cells according to their proliferation following Ag recognition [Mannering et al., J.ImmunolMethods 283 : 173, 2003] Other methods suitable for detecting cell proliferation (e.g. BrdU incorporation, Ki67 expression) may also be used. Besides being suitable for detecting the population of antigen-specific CD4+ T cells, said methods allows the direct sorting and/or cloning of the T cells of interest.
In some embodiments, the method of the present invention is particularly suitable for generating antigen-specific memory Thl, Th2 or Thl7 cells. The term "T helper cell" ("Th cell") refers to a subset of lymphocytes which complete maturation in the thymus and have various roles in the immune system, including the identification of specific foreign antigens in the body and the activation and deactivation of other immune cells. By this, T helper cells are involved in almost all adaptive immune responses. Mature Th cells are believed to always express the surface protein CD4 and are therefore also termed CD4+ T cells. As used herein, the term“Thl cell” and“Th2 cell” mean a type-1 helper T cell and a type-2 helper T cell, respectively. For instance Thl cells produce high levels of the proinflammatory cytokine IFNy Polarization in said T cell subset can be carried out by any conventional method well known in the art that typically consists in incubation the T cells with at least one cytokine (e.g. IL-12 for Thl cells). As used herein, the term“Thl7 cells” has its general meaning in the art and refers to a subset of T helper cells producing interleukin 17 (IL-17).“A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage”. Nat. Med. 13 (2): 139-145, 2007). The term“IL-17” has its general meaning in the art and refers to the interleukin-17A protein. Typically, Thl7 cells are characterized by classical expression of
Th cell markers at their cell surface such as CD4, and by the expression of IL-17. Typically, as referenced herein, a Thl7 cell is a IL-17+ cell.
In some embodiments, the method of the present invention further comprise a step consisting of polarizing the antigen-specific CD4+ T cells into a population of antigen-specific T regulatory cells.
As used herein, the term‘Treg’ or‘T regulatory cell’ denotes a T lymphocyte endowed with a given antigen specificity imprinted by the TCR it expresses and with regulatory properties defined by the ability to suppress the response of conventional T lymphocytes or other immune cells. Such responses are known in the art and include, but are not limited to, cytotoxic activity against antigen-presenting target cells and secretion of different cytokines. Different types of Tregs exist and include, but are not limited to: inducible and thymic-derived Tregs, as characterized by different phenotypes such as CD4+CD25+/high, CD4+CD25+/highCD127-/low alone or in combination with additional markers that include, but are not limited to, FoxP3, neuropilin-1 (CD304), glucocorticoid-induced TNFR-related protein (GITR), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD 152); T regulatory type 1 cells; T helper 3 cells. All these Tregs can be obtained either upon direct ex vivo purification or upon in vitro expansion or differentiation from the population of antigen-specific CD4+ T cells of the present invention. Examples of in vitro amplification protocols can be found in Battaglia et ah, J. Immunol. 177:8338-8347 (2006), Putnam et ah, Diabetes 58:652- 662 (2009), Gregori et al, Blood 116:935-944 (2009). Typically, the polarization consists in incubating the antigen-specific T helper cells with an amount of at least one cytokine such as TGFbeta.
The population of antigen-specific CD4+ T cells of the present invention is particularly suitable for adoptive cell therapy in subjects in need thereof.
For example, the population of antigen-specific CD4+ T cells of the present invention are suitable for the treatment of cancer. As used herein, the term "cancer" has its general meaning in the art and includes, but is not limited to, solid tumors and blood-borne tumors. The term cancer includes diseases of the skin, tissues, organs, bone, cartilage, blood and vessels. The term "cancer" further encompasses both primary and metastatic cancers. Examples of cancers that may be treated by methods and compositions of the invention include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant;
carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous; adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; and roblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra mammary paraganglioma, malignant; pheochromocytoma; glomangio sarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; Ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant;
chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non- Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia.
In some embodiments, the population of antigen-specific CD4+ T cells of the present invention are suitable for treating subjects afflicted with, or at risk of developing, an infectious disease, including but not limited to viral, retroviral, bacterial, and protozoal infections, etc. Subjects that can be treated include immunodeficient patients afflicted with a viral infection, including but not limited to CMV, EBV, adenovirus, BK polyomavirus infections in transplant patients, etc. Typically, the subjects at risk of developing an infectious disease include patients undergoing hematopoietic stem cell transplantation using peripheral blood or CB precursors. As used herein, the term "patient undergoing hematopoietic stem cell transplantation (HSCT)" refers to a human being who has to be transplanted with HSC graft. Typically, said patient is affected with a disorder which can be cured by HSCT. In some embodiments, the patient undergoing HSCT is affected with a disorder selected from the group consisting of leukemia, lymphoma, myeloproliferative disorders, myelodysplastic syndrome (MDS), bone marrow (BM) failure syndromes, congenital immunodeficiencies, enzyme deficiencies and hemoglobinopathies. In some embodiments, the HSCT is an allogeneic HSCT. As used herein, the term "allogeneic" refers to HSC deriving from, originating in, or being members of the same species, where the members are genetically related or not. An "allogeneic transplant" refers to transfer of cells or organs from a donor to a recipient, where the recipient is the same species as the donor. Allogeneic transplantation involves infusion of donor stem cells, typically using a donor that matches the recipient's MHC. However, matched unrelated donor (MUD) transplants are also associated with a stronger graft versus host reaction, and thus result in higher mortality rates. In another embodiment, the HSCT is an autologous HSCT. As used herein, the term "autologous" refers to deriving from or originating in the same subject or
patient. An "autologous transplant" refers to collection and retransplant of a subject's own cells or organs. Autologous transplantation involves infusion of a recipient's own cells following myeloablative treatment. Autologous cell transplants minimize the risk of graft versus host disease (GVHD) and result in reduced complications. Thus, the population of antigen-specific CD4+ T cells of the present invention are particularly suitable for preventing bacterial, viral, protozoal and/or fungal infection following CB HSCT. Non-limiting examples of viral infections include Herpes simplex virus (HSV) infections, CMV infections, Varicella-zoster virus (VZV) infections, Human herpes virus 6 (HHV6) infections, EBV infections, respiratory virus infections (such as respiratory syncytial virus (RSV), parainfluenza virus, rhinovirus, and influenza virus) and adenovirus infections. Non-limiting examples of bacterial infections include Gram-negative bacteria infections such as Escherichia (e.g. Escherichia coli), Salmonella, Shigella, and other Enterobacteriaceae, Pseudomonas (e.g. Pseudomonas aeruginosa), Moraxella, Helicobacter, and Legionella infections. Non-limiting examples of protozoal infections include Giardia infections (e.g. Giardia lamblia), Entamoeba infections (e.g. Entamoeba histolytica) and Toxoplasma (e.g. Toxoplasma gondii). Non-limiting examples of fungal infections include Aspergillus infection (e.g. Aspergillus fumigatus), Candida infection (e.g. Candida albicans and non-albicans Candida) and other emerging fungal infections including Trichosporon, Alternaria, Fusarium, and Mucorales infections.
In some embodiments, the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of autoimmune diseases. As used herein, the term“autoimmune disease” refers to the presence of an autoimmune response (an immune response directed against an auto- or self-antigen) in a subject. Autoimmune diseases include diseases caused by a breakdown of self-tolerance such that the adaptive immune system, in concert with cells of the innate immune system, responds to self- antigens and mediates cell and tissue damage. In some embodiments, autoimmune diseases are characterized as being a result of, at least in part, a humoral and/or cellular immune response. Examples of autoimmune disease include, without limitation, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti- GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal
and neuronal neuropathies, Behcet's disease, bullous pemphigoid, autoimmune cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathies, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA), Graves' disease, Guillain- Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, hypergammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, immunoregulatory lipoproteins, inclusion body myositis, inflammatory bowel disease, insulin-dependent diabetes (type 1), interstitial cystitis, juvenile arthritis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), monoclonal gammopathy of undetermined significance (MGUS), Mooren's ulcer, Mucha- Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), autoimmune neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Tumer syndrome, pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, type I, II, & III autoimmune polyglandular syndromes, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud’s phenomenon, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm & testicular autoimmunity, stiff person syndrome,
subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis/Giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, Waldenstrom's macroglobulinemia (WM), and Wegener's granulomatosis [Granulomatosis with Polyangiitis (GPA)]. In some embodiments, the autoimmune disease is selected from the group consisting of rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (lupus or SLE), myasthenia gravis, multiple sclerosis, scleroderma, Addison's Disease, bullous pemphigoid, pemphigus vulgaris, Guillain-Barre syndrome, Sjogren syndrome, dermatomyositis, thrombotic thrombocytopenic purpura, hypergammaglobulinemia, monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia (WM), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Hashimoto's Encephalopathy (HE), Hashimoto's Thyroiditis, Graves' Disease, Wegener's Granulomatosis [Granulomatosis with Poly angiitis (GPA)]. In some embodiments, the autoimmune disease is type 1 diabetes.
In some embodiments, the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of allergies. As used herein, the term“allergy” generally refers to an inappropriate immune response characterized by inflammation and includes, without limitation, food allergies, respiratory allergies and other allergies causing or with the potential to cause a systemic response such as, by way of example, Quincke’s oedema and anaphylaxis. The term encompasses allergy, allergic disease, hypersensitive associated disease or respiratory disease associated with airway inflammation, such as asthma or allergic rhinitis. In some embodiments, the method of the present invention is effective in preventing, treating or alleviating one or more symptoms related to anaphylaxis, drug hypersensitivity, skin allergy, eczema, allergic rhinitis, urticaria, atopic dermatitis, dry eye disease, allergic contact allergy, food hypersensitivity, allergic conjunctivitis, insect venom allergy, bronchial asthma, allergic asthma, intrinsic asthma, occupational asthma, atopic asthma, acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD). Hypersensitivity associated diseases or disorders that may be treated by the method of the present invention include, but are not limited to, anaphylaxis, drug reactions, skin allergy, eczema, allergic rhinitis, urticaria, atopic dermatitis, dry eye disease [or otherwise referred to as Keratoconjunctivitis sicca (KCS), also called keratitis sicca, xerophthalmia], allergic contact allergy, food allergy, allergic conjunctivitis, insect venom allergy and respiratory diseases associated with airway inflammation, for example, IgE mediated asthma and non-IgE mediated asthma. The respiratory diseases associated with airway inflammation may include, but are not
limited to, rhinitis, allergic rhinitis, bronchial asthma, allergic (extrinsic) asthma, non-allergic (intrinsic) asthma, occupational asthma, atopic asthma, exercise induced asthma, cough- induced asthma, acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD).
In some embodiments, the population of antigen-specific CD4+ T cells of the present invention having regulatory properties are suitable for the treatment of immune reactions against a grafted tissue or grafted hematopoietic cells or grafted blood cells. Typically the subject may have been transplanted with a graft selected from the group consisting of heart, kidney, lung, liver, pancreas, pancreatic islets, brain tissue, stomach, large intestine, small intestine, cornea, skin, trachea, bone, bone marrow, muscle, or bladder. The method of the present invention is also particularly suitable for preventing or suppressing an immune response associated with rejection of a donor tissue, cell, graft, or organ transplant by a recipient subject. Graft-related diseases or disorders include graft versus host disease (GVHD), such as associated with bone marrow transplantation, and immune disorders resulting from or associated with rejection of organ, tissue, or cell graft transplantation (e.g., tissue or cell allografts or xenografts), including e.g., grafts of skin, muscle, neurons, islets, organs, parenchymal cells of the liver, etc. Thus the method of the invention is useful for preventing Host-Versus-Graft- Disease (HVGD) and Graft- Versus-Host-Disease (GVHD). The population of antigen-specific CD4+ T cells may be administered to the subject before, during and/or after transplantation (e.g., at least one day before transplantation, at least one day after transplantation, and/or during the transplantation procedure itself). In some embodiments, the population of antigen-specific CD4+ T cells may be administered to the subject on a periodic basis before and/or after transplantation.
As used herein, the term "treatment" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction
period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at regular intervals, e.g., daily, weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
The population of antigen-specific CD4+ T cells of the present invention can be utilized in methods and compositions for adoptive cell therapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure. See, e.g., US Patent Application Publication No. 2003/0170238 to Gruenberg et al; see also US Patent No. 4,690,915 to Rosenberg. In some embodiments, the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount. Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin. A treatment-effective amount of cells in the composition is dependent on the relative representation of the antigen-specific T helper cells with the desired specificity, on the age and weight of the recipient, on the severity of the targeted condition and on the immunogenicity of the targeted Ags. These amount of cells can be as low as approximately 103/kg, preferably 5x103/kg; and as high as 107/kg, preferably 108/kg. The number of cells will depend upon the ultimate use for which the composition is intended, as will the type of cells included therein. For example, if cells that are specific for a particular Ag are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and 90-95% of such cells. If frequencies of antigen-specific T cells are insufficient, T cell lines can be enriched by cell sorting using tetramers or dextramers®; or MACS® cytokine secretion
assay (Miltenyi Biotec) For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 ml or less, even 250 ml or 100 ml or less. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed the desired total amount of cells.
As used herein, the term "administering" refers to administration of the compounds as needed to achieve the desired effect. Administration may include, but is not limited to, oral, sublingual, intramuscular, subcutaneous, intravenous, transdermal, topical, parenteral, buccal, rectal, and via injection, inhalation, and implants.
C) Methods of identifying a population of CD4+ T:
A further object of the present invention relates to a method of identifying a population of CD4+ T cells within a test population of T cells comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i) and iii) detecting whether a population of CD4+ T cells is activated and/or amplified.
In some embodiments, the population of T cells is isolated from a biological sample obtained from a subject/patient.
As used herein, the term“sample” to any biological sample obtained from the purpose of evaluation in vitro. The sample is typically a tissue sample or a body fluid sample. The term “tissue sample” includes sections of tissues such as biopsy or autopsy samples and frozen sections taken for histological purposes. In some embodiments, the tissue sample is a tumor tissue sample. The term“tumor tissue sample” means any tissue tumor sample derived from the patient. Said tissue sample is obtained for the purpose of the in vitro evaluation. In some embodiments, the tumor sample may result from the tumor resected from the patient. In some embodiments, the tumor sample may result from a biopsy performed in the primary tumour of the patient or performed in metastatic sample distant from the primary tumor of the patient. Examples of body fluids are blood, serum, plasma, amniotic fluid, brain/spinal cord fluid, liquor, cerebrospinal fluid, sputum, throat and pharynx secretions and other mucous membrane secretions, synovial fluids, ascites, tear fluid, lymph fluid and urine. More particularly, the sample is a blood sample. As used herein, the term“blood sample” means a whole blood sample obtained from the patient.
For example, the method can be used to screen for the ability of a test agent (e.g. a vaccine.) to elicit a particular antigen-specific population of CD4+ T cells. This method would involve administering to the subject the test agent, obtaining sample comprising a population
of T cells and performing the method of the present invention for determining whether the antigen-specific population of CD4+ T cells can be activated and/or amplified.
In some embodiments, the method of the present invention is also particularly suitable for determining if a subject has been exposed to (or is presently exposed to) one or more particular antigens. For instance, the method of the invention can be used to see if a subject has any immunity left from previous vaccinations/immunizations. Known antigens associated with a given vaccine, for example, can be used to detect and quantitate any effector cells present in a biological sample obtained from the subject. One can also use the method of the present invention to identify the best antigen or combinations of antigens for a particular vaccine (e.g. for a particular year's influenza vaccine). In particular, the method of the present invention is also particular suitable for optimizing an antigen for use in a vaccine. The method typically involves providing a plurality of antigens that are candidates for the vaccine; screening the antigens using any of the method of the present invention; and selecting an antigen that is capable of activating and/or the antigen-specific population of CD4+ T cells.
In some embodiments, the method of the present invention may also find application in diagnosis. For instance, the method of the present invention is particularly suitable for diagnosing infectious diseases, cancer and autoimmune diseases. For instance, the method of the present invention can be used to detect one or more antigen specific T cell responses which are correlated with the disease. The method of the present invention is also particularly suitable for monitoring immune therapy. As used herein, the term“monitoring immune therapy” refers to measurement of changes in T cell responses induced in a given subject following in vivo administration of immune modulating agents. For monitoring applications, different types of situations are found, according to the type of disease. In autoimmune diseases, immune modulatory therapies can be used to blunt pathological immune responses. One strategy to accomplish this result relies on non-Ag-specific interventions based on a number of immune modulatory agents. For example, said immune modulatory agents is an immunosuppressive drug. As used herein, the term“immunosuppressive treatment” refers to any substance capable of producing an immunosuppressive effect, e.g., the prevention or diminution of the immune response and in particular the prevention or diminution of the production of Ig. Immunosuppressive drugs include, without limitation thiopurine drugs such as azathioprine (AZA) and metabolites thereof; nucleoside triphosphate inhibitors such as mycophenolic acid (Cellcept) and its derivative (Myfortic); derivatives thereof; prodrugs thereof; and combinations thereof. Other examples include but are not limited to 6-mercaptopurine ("6-MP"), cyclophosphamide, mycophenolate, prednisolone, sirolimus, dexamethasone, rapamycin,
FK506, mizoribine, azothioprine and tacrolimus. Other examples also include calcineurin inhibitors and corticosteroids. Examples of corticosteroids include flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort and betamethasone corticosteroids, for example, cortisone, hydrocortisone, methylprednisolone, prednisone, prednisolone, betamethesone, beclomethasone dipropionate, budesonide, dexamethasone sodium phosphate, flunisolide, fluticasone propionate, triamcinolone acetonide, betamethasone, fluocinolone, fluocinonide, betamethasone dipropionate, betamethasone valerate, desonide, desoximetasone, fluocinolone, triamcinolone, triamcinolone acetonide, clobetasol propionate, and dexamethasone. Therefore it is of therapeutic interest to follow the immune changes induced by such intervention. Successful interventions should translate in a decrease (in the case of autoimmune diseases) or increase (in the case of cancer and infectious diseases) of the disease-related Ag-specific T cell responses. Such changes in disease-related Ag-specific T cell responses could be either quantitative or qualitative. Availability of these immune surrogate markers of clinical efficacy can be of great utility for a variety of applications. For example: better selection of patients to treat and therapeutic agents to use based on patient’s immune responses; optimization and/or tailoring of therapeutic doses or administration regimens (for example, increase in doses/frequency of administration if no immune change is registered), thus improving the risk-to-benefit ratio; prognostic stratification of treated patients according to their probability to respond to treatment; decision of whether to treat patients again based on maintenance or not of the induced immune changes. In some embodiments, the method of the present invention is particularly suitable for determining whether a subject is at risk of relapse. As used herein, the term "relapse" refers to the return of signs and symptoms of a disease after a subject has enjoyed a remission after a treatment. Thus, if initially the target disease is alleviated or healed, or progression of the disease was halted or slowed down, and subsequently the disease or one or more characteristics of the disease resume, the subject is referred to as being "relapsed."
D) Methods of determining identifying and/or characterizjns the T cell epitopes of an antisen:
A further object of the present invention relates to a method of determining identifying and/or characterizing the T cell epitopes of an antigen comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i), iii) detecting whether a population of CD4+ T cells is activated and/or amplified, iv) selecting the population of artificial antigen presenting cells that is capable of activating and/or amplifying
the population of CD4+ T cells, v) recovering and characterizing the peptides from the MHC class II molecules wherein said peptides represent the T cell epitopes of the antigen.
Typically, peptides are identified by the classical method of HLA-peptide complex extraction, peptide elution and subsequent peptide epitope identification by sequencing mass spectrometry. In particular, the method of the present invention comprises the steps of lyzing the population of artificial antigen presenting cells, recovering the MHC class II molecules typically in an immune affinity step, recovering the peptides from the MHC class II molecules and analyzing by mass spectrometry said peptides. In particular, the peptides are analyzed by LC-MS or LC-MS/MS that are the combination of liquid chromatography (LC) with mass spectrometry (MS). MS means you only analyze your precursor ion (as generated in the source) for example in an iontrap, a quadrupole or time-of-flight Massspec. MS/MS is the combination of two mass analyzers in one mass spectrometry instrument. The first MS filters for the precursor ion followed by a fragmentation of the precursor ion with high energy and e.g. nitrogen gas. A second mass analyzer is then filtering for the product ions, generated by the fragmentation. This is usually done in a triple quadrupole MS (QQQ) or a QTOF. The advantages of MS/MS is the increased and to can gain more structural information on the analyte (QTOF) based on the fragmentation pattern.
The method of the present invention is particularly suitable for determining protein antigenicity, identifying which antigens from an oncogene, virus, bacteria, pathogen, vaccine or other vector are actually presented by antigen presenting cells, discovering new peptide targets for cancer and infectious disease interventions, understanding the impact of protein modifications on immune responses...
For instance, the method of the present invention is thus particularly suitable for the in vitro study of the immunogenicity (or tolerogenicity) of therapeutic proteins. The term “therapeutic proteins” as used herein refers to protein or peptide compounds of any aminoacid length which are administered or are planned to be administered in vivo to human subjects to achieve a therapeutic effect. Examples of such therapeutic proteins are antibodies of different species (either in their native form or partially/fully humanized), cytokines, hormones or hormone analogues, coagulation factors, enzymes, bacterial or viral proteins. Such proteins are not limited to natural ones, but also include modified proteins or chimeric constructs, obtained for example by changing selected aminoacid sequences or by fusing portions of different proteins. In particular, there are two different therapeutic settings where evaluation of immunogenicity of therapeutic proteins is of relevance. One first therapeutic setting concerns the use of disease-associated antigens for in vivo administration, with the aim of inducing a
tolerogenic effect (e.g., in the case of autoimmune diseases) or an immunogenic effect (e.g., in the case of cancer or infectious diseases). It is important to first evaluate in vitro the potential to achieve said desired therapeutic effect. In other therapeutic settings, the aim is not to induce immunogenic responses of any kind to the administered protein, but rather to avoid such responses so to allow said protein to achieve the therapeutic effect for which it is designed. Example of such settings include, without being limited to, cytokine-based immune therapies, hormone replacement therapies and replacement therapies for coagulation factors (e.g., Factor VIII in Haemophilia A) or enzymatic deficits (e.g., beta-glucuronidase in mucopolysaccharidosis VII). In all these situations, mounting of immunogenic responses against the administered protein is not desirable, as this would be counterproductive for achieving the desired therapeutic effect (e.g., side effects such as cytokine release syndromes; or neutralization/degradation of the therapeutic protein).
Another application of the method of the present invention is its use for Ag or epitope discovery (also known as“mapping”), i.e. for screening Ags and epitopes in order to select those eliciting an Ag-specific T cell response.
E) Kits of the present invention:
Other aspects of the present invention include kits for carrying out the methods of the present invention. A kit may include the population of AAPC of the present invention and materials useful such as a device (e.g. a 96-well plate in which the AAPCs and the T cells are cocultured). Different combinations of such materials may be organized as a kit in order to aid the skilled artisan in carrying out the methods of the present invention.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1 Phenotype of the AAPCDR1 cell lines. Expression of transduced molecules: the eight Ag-encoding AAPCDR1 cell lines and the AAPCDR1 cell line were stained with anti-human CD54, CD58, CD80 and HLA-DR antibodies. Fluorescence black histograms show the expression levels of transduced molecules. The white histograms represent isotype controls (A). Expression of mouse MHC-II molecules: mouse splenocytes, NIH/3T3 cells and the AAPCDR1 cell line were stained with an anti-mouse I-A/I-E antibody. Fluorescence black histograms show the expression levels of mouse“classical” MHC-II molecules (I-A/I-E; H-2A, H-2E). The white histograms represent isotype control (B).
Figure 2 Peptide Ag presentation by the AAPCDR1 cell lines. AAPCDR1 or B-EBVDR1 cell lines loaded with HA or control peptide (A), HA peptide-encoding AAPCDR1 cell lines (B) or HA protein-encoding AAPCDR1 cell lines were used to stimulate the HA-specific CD4+ T- cell clone (C). Several ratios of stimulating cells to T cells (1 : 1, 1 : 3 and 1 : 9) were performed to discriminate the Ag presentation ability of the AAPCDR1 cell lines. Frequencies of activated TLs were evaluated by intracellular IFN-g staining and FACS analysis. Results show percentages of IFN-y+ cells among CD4+ TLs. A representative experiment from three independent experiments is shown.
Figure 3 Priming of CD4+ TLs by the AAPCDR1 cell lines or by autologous PBMCs. The AAPCdr1 cell lines expressing HA peptide in the ER or HA protein at the plasma membrane, or the AAPCDR1 cell line loaded with 10 pg/ml of HA peptide were used to stimulate purified CD4+ TLs for 14 days. Alternatively, autologous PBMCs were cultured with 10 pg/ml of HA peptide for the same duration. Frequency of HA-specific CD4+ effector TLs was evaluated by DR1-HA (or control DR1-CLIP) tetramer staining at day 14. Results show percentages of HA-tetramer+ cells among CD4+ TLs. A representative experiment is shown from four independent experiments with four donors (A) For the same primary culture condition, intracellular IFN-g staining was also performed after reactivation by the B-EBVDR1 cell line loaded with 10 pg/ml of HA or control peptide. Results show percentages of IFN-y+ cells among CD4+ TLs. A representative experiment is shown from six independent experiments with six donors (B).
Figure 4 Re-stimulation of CD4+ TLs by the AAPCDR1 cell lines or by autologous PBMCs. TLs generated after primary culture of autologous PBMCs loaded with lOpg/ml of HA peptide for 14 days were re-stimulated for 7 additional days by the AAPCDR1 cell lines expressing HA peptide in the ER or HA protein at the plasma membrane, or by the AAPCDR1 cell line or autologous PBMCs loaded with 10 pg/ml of HA peptide. Frequency of HA-specific CD4+ effector TLs was evaluated by DR1-HA (or control DR1-CLIP) tetramer staining at day 21. Results show percentages of HA-tetramer+ cells among CD4+ TLs. For the same re stimulation conditions, the naive/memory phenotype of the generated CD4+ TLs was harvested by flow cytometry using the following antibodies: anti-human CD45RO, CD45RA, CD62L and CCR7. Results show percentages of cells subsets among CD4+ HA-tetramer+ TLs (A). At days 14 and 21, the percentages and absolute numbers of HA-specific TLs were evaluated by tetramer staining. A representative experiment is shown from four independent experiments with four donors (B). They were also evaluated by intracellular IFN-g staining. A representative
experiment is shown from six independent experiments with six donors (C).*P<0.05 (repeated measures of one-way ANOVA analysis followed by Dunnett’s post test); ns, not significant.
Figure 5. Ag addressing strategies to target the MHC-II Ag presentation pathway. HA protein addressing strategies were developed to target the plasma membrane, the cytoplasm, endosomes, and the extracellular media. Excepted for the native HA protein which is addressed to the plasma membrane, the others approaches are based on the use of the extracellular domain of HA, coupling or not, to a specific signal peptide to reach the targeted cell compartment (A). HA peptide addressing strategies were developed to target the cytoplasm, the ER, endosomes and the extracellular media. HA peptide is coupling, or not, to a specific signal peptide to reach the targeted cell compartment (B). TM: Transmembrane domain, Vtg: Vitellogenin.
EXAMPLE:
Methods
Healthy donors and CD4+ TLs purification
Peripheral blood from HLA-DRB 1*01 :01+ (HLA-DRl) healthy donors of the French Blood Service (EFS Hauts de France, Caen, France) was collected in heparin tubes, after informed consent was obtained. PBMCs were isolated by density gradient centrifugation on lymphocyte separation medium (Eurobio, Courtaboeuf, France). CD4+ TLs were isolated from PBMCs by negative magnetic purification, using the Dynabead Untouched Human CD4 T Cells Kit (ThermoFischer Scientific, Illkirch, France), according to the manufacturer’s protocol.
Design of strategies for the targeting of Ag in MHC-II pathway compartments and construction of AAPCDR1 cell lines
The viral Ag of hemagglutinin (HA, Influenza A H3N2, strain A/ Ai chi/2/1968) used in this study is a transmembrane protein of 566 amino acids. It is consisted of a signal peptide (HAi-ΐd), an extracellular domain (HA17-530) which contains the epitope HA306-318 restricted to the HLA-DRl context, a transmembrane domain (HA531-551) and by a cytoplasmic domain (HA552-566). Nine novels Ag-encoding AAPCDR1 were constructed. The first one was transduced with a vector encoding the whole HA protein (Figure 5A). For the others HA protein-encoding AAPCDR1, the signal peptide, transmembrane and cytoplasmic domains of the protein were deleted to ameliorate Ag trafficking. In this condition, without signal peptide, the HA protein can be express in the cytoplasm. The extracellular domain of HA protein was coupled to the signal peptide of the glycoprotein 75 (gp75) via a linker to target endosomes, or to the secretion signal peptide of the vitellogenin (Vtg) in order to induce secretion of the protein.18-20 Using the same approaches, the HA306-3 is peptide was used to target the cytoplasm, endosomes and
the extracellular media (Figure 5B). To target the ER, HA306-318 peptide was coupled to the CD8a signal peptide, as we previously described.21
The sequences are depicted as follows:
SEQ ID NO: 3 (Membrane HA protein (Membr HA prot)
CTCGAGGCCACCATGAAGACCATCATTGCCCTGAGCTACATCTTCTGCCTGGCTCTGGGCCAGGACCTG CCCGGCAACGACAACAGCACCGCCACCCTGTGTCTGGGCCACCACGCCGTGCCTAACGGCACCCTGGTG AAAACCATCACCGACGACCAGATCGAAGTGACCAACGCCACCGAGCTGGTGCAGAGCAGCAGCACCGGC AAGATCTGCAACAACCCTCACAGAATCCTGGACGGCATCGACTGCACCCTGATCGACGCCCTGCTGGGC GACCCTCACTGCGACGTGTTCCAGAACGAGACATGGGACCTGTTCGTGGAAAGAAGCAAGGCCTTCAGC AACTGCTACCCCTACGACGTGCCCGACTACGCCAGCCTGAGAAGCCTGGTGGCCAGCAGCGGCACACTG GAATTCATCACCGAGGGCTTCACCTGGACCGGCGTGACCCAGAACGGCGGCAGCAACGCCTGCAAGAGA GGCCCTGGCAGCGGCTTCTTCAGCAGACTGAACTGGCTGACCAAGAGCGGCTCCACCTACCCCGTGCTG AACGTGACCATGCCCAACAACGACAACTTCGACAAGCTGTACATCTGGGGCATCCACCACCCCAGCACC AACCAGGAACAGACCAGCCTGTACGTGCAGGCCAGCGGCAGAGTGACCGTGTCCACCAGAAGAAGCCAG CAGACCATCATCCCCAACATCGGCAGCAGACCCTGGGTCCGCGGCCTGAGCAGCAGAATCAGCATCTAC TGGACCATCGTGAAGCCCGGCGACGTGCTGGTCATCAACAGCAACGGCAACCTGATCGCCCCTAGAGGC TACTTCAAGATGAGAACCGGCAAGAGCAGCATCATGAGAAGCGACGCCCCTATCGACACCTGTATCAGC GAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCCTTCCAGAACGTGAACAAGATCACCTAC GGCGCCTGCCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCGGCATGAGAAACGTGCCCGAG AAGCAGACCAGAGGCCTGTTCGGCGCTATCGCCGGCTTCATCGAGAACGGCTGGGAGGGCATGATCGAC GGGTGGTACGGCTTCAGACACCAGAACAGCGAGGGCACCGGCCAGGCCGCCGACCTGAAGTCTACACAG GCCGCCATCGACCAGATCAACGGCAAGCTGAACAGAGTGATCGAAAAGACCAACGAGAAGTTCCACCAG ATCGAGAAAGAATTCAGCGAGGTGGAAGGCAGAATCCAGGACCTGGAAAAGTACGTGGAAGATACCAAG ATCGACCTGTGGTCCTACAACGCCGAGCTGCTGGTGGCCCTGGAAAACCAGCACACCATCGACCTGACC GACAGCGAGATGAACAAGCTGTTCGAGAAAACCAGAAGGCAGCTGCGCGAGAACGCCGAGGAAATGGGC AACGGCTGCTTCAAGATCTACCACAAGTGCGACAACGCCTGTATCGAGAGCATCAGAAACGGCACCTAC GACCACGACGTGTACAGGGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGCGTGGAACTGAAGTCC GGCTACAAGGACTGGATTCTGTGGATCAGCTTCGCTATCAGCTGCTTCCTGCTGTGCGTGGTGCTGCTG GGCTTCATCATGTGGGCCTGCCAGAGGGGCAACATCAG ATGCAACATCTGCATC TGAGAGGATCC
SEQ ID NO: 4 Cytoplasmic HA protein (Cyto HA prot)
CTCGAGGCCACCATGCAGGACCTGCCCGGCAACGACAACAGCACCGCCACCCTGTGTCTGGGCCACCAC
GCCGTGCCTAACGGCACCCTGGTGAAAACCATCACCGACGACCAGATCGAAGTGACCAACGCCACCGAG
CTGGTGCAGAGCAGCAGCACCGGCAAGATCTGCAACAACCCTCACAGAATCCTGGACGGCATCGACTGC
ACCCTGATCGACGCCCTGCTGGGCGACCCTCACTGCGACGTGTTCCAGAACGAGACATGGGACCTGTTC
GTGGAAAGAAGCAAGGCCTTCAGCAACTGCTACCCCTACGACGTGCCCGACTACGCCAGCCTGAGAAGC
CTGGTGGCCAGCAGCGGCACACTGGAATTCATCACCGAGGGCTTCACCTGGACCGGCGTGACCCAGAAC
GGCGGCAGCAACGCCTGCAAGAGAGGCCCTGGCAGCGGCTTCTTCAGCAGACTGAACTGGCTGACCAAG
TCCGGCAGCACCTACCCCGTGCTGAACGTGACCATGCCCAACAACGACAACTTCGACAAGCTGTACATC
TGGGGCATCCACCACCCCAGCACCAACCAGGAACAGACCAGCCTGTACGTGCAGGCCAGCGGCAGAGTG
ACCGTGTCCACCAGAAGAAGCCAGCAGACCATCATCCCCAACATCGGCAGCAGACCCTGGGTCCGCGGC CTGAGCAGCAGAATCAGCATCTACTGGACCATCGTGAAGCCCGGCGACGTGCTGGTCATCAACAGCAAC GGCAACCTGATCGCCCCTAGAGGCTACTTCAAGATGAGAACCGGCAAGAGCAGCATCATGAGAAGCGAC GCCCCTATCGACACCTGTATCAGCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCCTTC CAGAACGTGAACAAGATCACCTACGGCGCCTGCCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCC ACCGGCATGAGAAACGTGCCCGAGAAGCAGACCAGAGGCCTGTTCGGCGCTATCGCCGGCTTCATCGAG AACGGCTGGGAGGGCATGATCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAGGGCACCGGCCAG GCCGCCGACCTGAAGTCTACACAGGCCGCCATCGACCAGATCAACGGCAAGCTGAACAGAGTGATCGAA AAGACCAACGAGAAGTTCCACCAGATCGAGAAAGAATTCAGCGAGGTGGAAGGCAGAATCCAGGACCTG GAAAAGTACGTGGAAGATACCAAGATCGACCTGTGGTCCTACAACGCCGAGCTGCTGGTGGCCCTGGAA AACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAAACCAGAAGGCAGCTG CGCGAGAACGCCGAGGAAATGGGCAACGGCTGCTTCAAGATCTACCACAAGTGCGACAACGCCTGTATC GAGAGCATCAGAAACGGCACCTACGACCACGACGTGTACAGGGACGAGGCCCTGAACAACAGATTCCAG ATCAAGGGCGTGGAACTGAAGTCCGGCTACAAGGATTGGTGAGAGGATCC
SEQ ID NO: 5 Endosomal HA protein (Endo HA prot)
CTCGAGGCCACCATGCAGGACCTGCCCGGCAACGACAACAGCACCGCCACCCTGTGTCTGGGCCACCAC GCCGTGCCTAACGGCACCCTGGTGAAAACCATCACCGACGACCAGATCGAAGTGACCAACGCCACCGAG CTGGTGCAGAGCAGCTCCACCGGCAAGATCTGCAACAACCCTCACAGAATCCTGGACGGCATCGACTGC ACCCTGATCGACGCCCTGCTGGGCGACCCTCACTGCGACGTGTTCCAGAACGAGACATGGGACCTGTTC GTGGAAAGAAGCAAGGCCTTCAGCAACTGCTACCCCTACGACGTGCCCGACTACGCCAGCCTGAGAAGC CTGGTGGCCAGCAGCGGCACACTGGAATTCATCACCGAGGGCTTCACCTGGACCGGCGTCACCCAGAAC GGCGGCAGCAACGCCTGCAAGAGAGGCCCTGGCAGCGGCTTCTTCAGCAGACTGAACTGGCTGACCAAG AGCGGCAGCACCTACCCCGTGCTGAACGTGACCATGCCTAACAACGACAACTTCGACAAGCTGTACATC TGGGGCATCCACCACCCCAGCACCAACCAGGAACAGACCAGCCTGTACGTGCAGGCCAGCGGCAGAGTG ACCGTGTCCACCAGAAGAAGCCAGCAGACCATCATCCCCAACATCGGCAGCAGACCCTGGGTCCGGGGC CTGAGCAGCAGAATCAGCATCTACTGGACCATCGTGAAGCCCGGCGACGTGCTGGTGATCAACAGCAAC GGCAACCTGATCGCCCCTAGAGGCTACTTCAAGATGAGAACCGGCAAGAGCAGCATCATGAGAAGCGAC GCCCCTATCGACACCTGTATCAGCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCCTTC CAGAACGTGAACAAGATCACCTACGGCGCCTGCCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCC ACCGGCATGAGAAACGTGCCCGAGAAGCAGACCAGAGGCCTGTTCGGCGCTATCGCCGGCTTCATCGAG AACGGCTGGGAGGGCATGATCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAGGGCACCGGCCAG GCCGCCGACCTGAAGTCTACACAGGCCGCCATCGACCAGATCAACGGCAAGCTGAACAGAGTGATCGAA AAGACCAACGAGAAGTTCCACCAGATCGAGAAAGAATTCAGCGAGGTGGAAGGCAGAATCCAGGACCTG GAAAAGTACGTGGAAGATACCAAGATCGACCTGTGGTCCTACAACGCCGAGCTGCTGGTGGCCCTGGAA AACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAAACCAGAAGGCAGCTG CGCGAGAACGCCGAGGAAATGGGCAACGGCTGCTTCAAGATCTACCACAAGTGCGACAACGCCTGTATC GAGAGCATCAGAAACGGCACCTACGACCACGACGTGTACAGGGACGAGGCCCTGAACAACAGATTCCAG
ATCAAGGGCGTGGAACTGAAGTCCGGCTACAAGGATTGGAGCGGCGGCAGCGGCGGATCTGGCGGCATC
ATCACAATCGCCGTGGTGGCCGCCCTGCTGCTGGTGGCTGCTATCTTCGGCGTGGCCAGCTGCCTGATC
AGAAGCAGAAGCACCAAGAACGAGGCCAACCAGCCCCTGCTGACCGACCACTACCAGCGCTACGCCGAG GACTACGAGGAACTGCCCAACCCCAACCACAGCATGGTCTGAGAGGATCC
SEQ ID NO: 6 Extracellular HA protein (Extracell HA prot)
CTCGAGGCCACCATGAGAGTGCTGGTGCTGGCCCTGGCCGTGGCTCTGGCTGTGGGCGATCAGAGCAAC
CTGGGCCAGGACCTGCCCGGCAACGACAACAGCACCGCCACCCTGTGTCTGGGCCACCACGCCGTGCCT
AACGGCACCCTGGTGAAAACCATCACCGACGACCAGATCGAAGTGACCAACGCCACCGAGCTGGTGCAG
AGCAGCTCCACCGGCAAGATCTGCAACAACCCTCACAGAATCCTGGACGGCATCGACTGCACCCTGATC
GACGCCCTGCTGGGCGACCCTCACTGCGACGTGTTCCAGAACGAGACATGGGACCTGTTCGTGGAAAGA
AGCAAGGCCTTCAGCAACTGCTACCCCTACGACGTGCCCGACTACGCCAGCCTGAGAAGCCTGGTGGCC
AGCAGCGGCACACTGGAATTCATCACCGAGGGCTTCACCTGGACCGGCGTGACCCAGAACGGCGGCAGC
AACGCCTGCAAGAGAGGCCCTGGCAGCGGCTTCTTCAGCAGACTGAACTGGCTGACCAAGAGCGGCAGC
ACCTACCCCGTGCTGAACGTGACCATGCCCAACAACGACAACTTCGACAAGCTGTACATCTGGGGCATC
CACCACCCCAGCACCAACCAGGAACAGACCAGCCTGTACGTGCAGGCCAGCGGCAGAGTGACCGTGTCC
ACCAGAAGAAGCCAGCAGACCATCATCCCCAACATCGGCAGCAGACCCTGGGTCCGGGGCCTGAGCAGC
AGAATCAGCATCTACTGGACCATCGTGAAGCCCGGCGACGTGCTGGTGATCAACAGCAACGGCAACCTG
ATCGCCCCTAGAGGCTACTTCAAGATGAGAACCGGCAAGAGCAGCATCATGAGAAGCGACGCCCCTATC
GACACCTGTATCAGCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCCTTCCAGAACGTG
AACAAGATCACCTACGGCGCCTGCCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCGGCATG
AGAAACGTGCCCGAGAAGCAGACCAGAGGCCTGTTCGGCGCTATCGCCGGCTTCATCGAGAACGGCTGG
GAGGGCATGATCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAGGGCACCGGCCAGGCCGCCGAC
CTGAAGTCTACACAGGCCGCCATCGACCAGATCAACGGCAAGCTGAACAGAGTGATCGAAAAGACCAAC
GAGAAGTTCCACCAGATCGAGAAAGAATTCAGCGAGGTGGAAGGCAGAATCCAGGACCTGGAAAAGTAC
GTGGAAGATACCAAGATCGACCTGTGGTCCTACAACGCCGAGCTGCTGGTGGCCCTGGAAAACCAGCAC
ACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAAACCAGAAGGCAGCTGCGCGAGAAC
GCCGAGGAAATGGGCAACGGCTGCTTCAAGATCTACCACAAGTGCGACAACGCCTGTATCGAGAGCATC
AGAAACGGCACCTACGACCACGACGTGTACAGGGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGC
GTGGAACTGAAGTCCGGCTACAAGGATTGGTGAGAGGATCC
SEQ ID NO: 7 Cytoplasmic HA peptide (Cyto HA pept)
CTCGAGGCCACCATGCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCTGAGAGGATCC
SEQ ID NO: 8 Endoplasmic Reticulum HA peptide (ER HA pept)
CTCGAGGCCACCATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCCCTGGCTCTGCTGCTGCACGCCTCC
CAGGCCCCTAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCTGAGAGGATCC
SEQ ID NO: 9 Endosomal HA peptide (Endo HA pept)
CTCGAGGCCACCATGCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCAGCGGCGGAAGCGGA
GGATCTGGCGGCATCATCACAATCGCCGTGGTGGCTGCTCTGCTGCTGGTGGCAGCCATCTTTGGCGTG
GCCTCTTGCCTGATCAGAAGCAGATCCACCAAGAACGAGGCCAACCAGCCCCTGCTGACCGACCACTAC
CAGAGATACGCCGAGGACTACGAGGAACTGCCCAACCCCAACCACAGCATGGTCTAAGAGGATCC
SEQ ID NO: 10 Extracellular HA peptide (Extracell HA pept)
CTCGAGGCCACCATGAGAGTGCTGGTGCTGGCCCTGGCCGTGGCTCTGGCTGTGGGCGATCAGAGCAAC
CTGGGCCCCAAATACGTGAAGCAGAACACCCTGAAGCTGGCCACCTGAGAGGATCC
All Ag-encoding complementary DNAs (cDNAs) were synthesized and purchased from GeneArt® (ThermoFischer Scientific). These cDNAs were optimized for Ag translation in mus musculus organism to favor their expression in NIH/3T3 based AAPCs. The construction of NIH/3T3 -derived AAPCDR1 was previously described.14 The cDNAs encoding addressed Ags were subcloned into dicistronic gammaretrovirus-derived SFG vectors expressing puromycin- N-acetyltransferase. All constructs were verified by Sanger DNA sequencing. H29/293 GPG packaging cells were transfected with each vector, using the calcium chloride precipitation method.22 AAPCDR1 were genetically modified by sequential infections with cell-free gammaretroviral supernatants corresponding to the Ag of interest (Ag-encoding AAPCDR1), in the presence of 8pg/ml of polybrene (Sigma-Aldrich, Saint-Quentin Fallavier, France) for 16 h. Cells transduced by dicistronic vector were selected with 5pg/ml of puromycin (Sigma- Aldrich). AAPCdr1 cell lines were cultured in DMEM (ThermoFischer Scientific) supplemented with 10% of decomplemented AB human serum (Sigma-Aldrich).
RNA extraction from AAPCDR1 and mouse splenocytes followed by two-step RT-
PCRs
Mouse splenocytes were kindly provided by G Riou (Inserm U1234, University of Rouen Normandy, Rouen, France). RNAs of AAPCDR1 and mouse splenocytes were extracted from 5.106 cells using the NucleoSpin RNA isolation kit (Macherey-Nagel, Easton, PA, USA) according to the manufacturer’s protocol. cDNAs were generated from200 ng of total using oligo (dT) and random sequence primers (Random Hexamer) and Verso™ cDNA kit (Thermo Fischer Scientific), according to the manufacturer's instructions. cDNAs were PCR-amplified obtained using primers (Eurogentec SA, Liege, Belgium).
Peptide Ags
Two peptides were used in this study. The HA306PKYVKQNTLKLAT318 (SEQ ID NO: 11) peptide of H3N2 influenza virus restricted to the HLA-DR1 molecule presentation was used as the peptide of interest. The Myelin Basic Protein, MBP84DENPVVHFFKNIVTPRTPP102 (SEQ ID NO: 12) peptide was used as a control peptide. These peptides were kindly provided by Dr J Leprince and B Lefranc (Inserm U1239, University of Rouen Normandy, Rouen, France).
T-cell clone and B-EBVDR1 cell lines
CD4+ T-cell clone Flu-2, specific for HA306-318 peptide, was kindly provided by Pr A Godkin (Institute of Infection and Immunity, Cardiff, UK).23 The homozygous ULA-DR1+ B- EBV cell line was a kind gift from Dr H Vie (Inserm UMR 1232, Nantes, France). Culture of the T-cell clone was performed in 96-well U bottom plates in RPMI (ThermoFischer Scientific), supplemented with 1% of Fetal Calf Serum (FCS, ThermoFischer Scientific), 2 mM of glutamine (ThermoFischer Scientific), 50 IU/ml of penicillin (ThermoFischer Scientific) and 50 pg/ml of streptomycin (ThermoFischer Scientific). Culture of HLA-DRU B-EBV cell line was performed in RPMI supplemented with 10% of FCS (Fetal Calf Serum, ThermoFischer Scientific).
Cell membrane staining
AAPCdr1 were stained for 20-30 min at 4°C in phosphate-buffered saline/bovine serum albumin/ethylenediamine tetraacetic acid (PBS/BSA/EDTA) buffer with the following antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-mouse I-A/I-E (BioLegend, London, UK), FITC-conjugated anti-human CD58 (BD Biosciences, Piscataway, NJ, USA) and FITC-conjugated anti-human CD54, CD80 and HLA-DR (all from ThermoFischer Scientific). In the same conditions, TLs were stained with the following antibodies: FITC-conjugated anti human CD4, phycoerythrin (PE)/Cyanine 7 (Cy7)-conjugated anti-human CD45RA, peridinin chlorophyll protein complex (PerCP)/Cyanine 5.5 (Cy5.5)-conjugated anti-human CD45RO, allophycocyanin (APC)-conjugated anti-human CCR7, APC/Cy7-conjugated anti-human CD62L, PerCP/Cy5.5 -conjugated anti-human PD-1 (all from ThermoFischer Scientific), APC/Cy7-conjugated anti-human CD3, brillant violet (BV)786-conjugated anti-human CD8, APC-conjugated anti-human CTLA-4, BV711 -conjugated anti-human TIM-3 (all from Sony Biotechnology, Weybridge, UK) and BV421 -conjugated anti-human TIGIT (BioLegend). CTLA-4 expression was also detected by intracellular staining as described below. Frequency of HA-specific CD4+ TLs was assessed by tetramer staining for 30 min at room temperature with PE-conjugated ULADRB1 *01 :01-HA (DR1-HA, Prolmmune, Oxford, UK) or control HLA-DRB 1*01 :01 -CLIP tetramers (DRl-CLIP, a kind gift of the NIH Tetramer Core Facility, Atlanta, GA, USA). Cells were analyzed using BD LSRFortessa cytometer (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA).
Intracellular staining
For intracellular cytokine staining, TLs were treated using the Intraprep Permeabilization Reagent kit (Beckman Coulter, Villepinte, France) according to the manufacturer’s protocol. TLs were stained with the following antibodies: APC-conjugated anti-
human IFN-g, PE-conjugated anti-human TNF-a, PE-conjugated anti-human granzyme B (all from ThermoFischer Scientific) and APC-conjugated anti-human perforin (Sony Biotechnology).
Stimulation of the T-cell clone
For evaluation of Ag presentation, CD4+ T-cell clone (105 per well) was cultured for 6 h with AAPCDR1 or B-EBVDR1 cell lines (105 per well for an APC : TL ratio of 1 : 1) previously loaded for 1 hour with 10 pg/ml of HA or MBP control peptide or cultured with Ag-encoding AAPCdr1 cell lines (105 per well for an APC : TL ratio of 1 : 1). Brefeldin A at 10 pg/ml (Sigma- Aldrich) was added for the last 5 h of incubation before intracellular cytokine staining.
Stimulation of purified CD4+ TLs by AAPCDR1 or PBMCs
For primary stimulation experiments, irradiated (25 Gy) Ag-encoding AAPCDR1 cell lines or irradiated AAPCDR1 loaded for 1 hour with 10pg/ml of HA or control peptides were plated (1.5 >< 105 per well) 4 hours before incubation with purified CD4+ TLs from healthy subjects (lxlO6 per well) for 14 days. Alternatively, PBMCs (2/ 106 per well) were incubated with 10 pg/ml of HA or control peptides for the same duration. For re-stimulation experiments, effector TLs (lxlO6 per well) generated by primary culture of PBMCs pulsed with HA peptide were incubated with either irradiated (25 Gy) adherent Ag-encoding AAPCDR1 cell lines (1.5 x l05 per well), or either AAPCDR1 (1.5 x l05 per well) or autologous PBMCs (2x l06 per well) loaded with 10 pg/ml of HA or control peptides for 7 days. Cultures were performed in 24-well plates with AIM-V CTS medium (ThermoFischer Scientific) supplemented with 2 mM of glutamine (ThermoFischer Scientific) and 5% of decomplemented human AB serum (Sigma- Aldrich). On day 4, and then every other day, 20 IU/ml of interleukin-2 (R&D Systems, Lille, France) was added.
Statistics
Prism software (GraphPad software, La Jolla, CA, USA) was used to perform repeated measures of one-way ANOVA analysis followed by Dunnett’s post test.
Results
Ag-encoding AAPCDR1 express molecules required to activate human CD4+ TLs but not mouse molecules involved in MHC-II Ag presentation pathway
AAPCdr1 were constructed by gammaretroviral transduction of mouse fibroblasts NIH/3T3 with vectors encoding HLA-DRa, HLA-DRp l *01 :01 (HLA-DRl), CD80 co stimulatory and CD54 and CD58 adhesion molecules. To obtain Ag-encoding AAPCDR1 cell lines, AAPCDR1 were additionally transduced with different constructs expressing the HA viral Ag, in the form of a protein or a peptide, and addressing the Ag to a particular cellular
compartment (Figure 5A and 5B). After transduction, AAPCDR1 and the eight Ag-encoding AAPCdr1 cell lines presented high expression and comparable levels of HLA-DR, CD80, CD54 and CD58 molecules (Figure 1A). NIH/3T3 or AAPCDR1 do not express the classical mouse MHC-II molecules (I-A and I-E) at their surface (Figure IB) neither the mouse invariant chain nor the“non-classical” mouse MHC-II molecules (H-2M and H-20), which are all involved in the mouse MHC-II Ag presentation pathway (data not shown). Taken together, these data indicates that these AAPCs are well equipped to activate human but not mouse CD4+ T cells.
Ag-encoding AAPCDR1 cell lines efficiently process proteins and present peptide
Ags
To assess the ability of the novels Ag-encoding AAPCDR1 cell lines to present Ags, we used a CD4+ T-cell clone that recognizes the HA306-318 epitope, restricted to the HLA-DRl context. Several ratios of AAPCs to T-cell clone were used in order to compare their stimulatory ability. As previously described, AAPCDR1 loaded with HA peptide were very efficient to activate the specific T-cell clone, at a higher level than B-EBVDR1 cells (Figure 2A) Among the eight HA Ag-encoding AAPCs, those expressing HA peptide in the ER and those expressing HA protein at the plasma membrane are the most powerful stimulatory cells (Figure 2B and 2C). These both AAPCs have similar Ag presentation ability than AAPCDR1 loaded with HA peptide. In contrast, AAPCDR1 expressing HA Ag in the cytoplasm have the lowest stimulatory capacities.
Ag-encoding AAPCDR1 prime human CD4+ T cells at lower level than autologous
APCs
Next, we selected AAPCDR1 expressing HA peptide in the ER and HA protein at the cell surface, and evaluated their ability to prime human CD4+ T cell response. The two HA Ag- encoding AAPCdr1 were able to generate HA-specific CD4+ T cell with the same efficacy than AAPCdr1 pulsed with HA peptide. HA-tetramer staining and IFN-g production after reactivation with B-EBVDR1 cells show about 1,5 to 3% specific CD4+ T cells (Figure 3A and 3B). However, autologous PBMCs pulsed with HA peptide were more effective to prime CD4+ T cells, resulting in 15% of CD4+/HA-tetramer+ cells but also in 10,9% of CD4+/IFN-y+ cells after B-EBVDR1 reactivation.
Ag-encoding AAPCDR1 expressing HA peptide in the ER are more effective to reactivate memory specific CD4+ T cell than autologous APCs
Effectors generated in primary culture by stimulating CD4+ T cells with PBMCs pulsed with HA peptide were re-stimulated by AAPCs or autologous APCs. AAPCDR1 pulsed with HA peptide and the two HA Ag-encoding AAPCDR1 generated superior frequencies of memory
specific CD4+ T cells than autologous PBMCs as assessed by tetramer or IFN-g staining (Figure 4A, 4B, and 40. In term of absolute number, AAPCDR1 encoding HA peptide in the ER is significantly the more effective stimulating cells for amplifying memory T cells (Figure 4B and 40. After re-stimulation by autologous PBMCs or by AAPCs, HA-specific CD4+ TLs were IFN-g and TNF-a producing Thl cells with a similar naif/memory phenotype including a majority of effector memory T cells (TEM; CD45RO+, CD62L , CCR7 ) (Figure 4A and 40. The other cells were transitional memory (TTM; CD45RO+, CD62L+, CCR7 ). A contingent of CD4+ T cells produce granzyme B but not perforin after reactivation with the HA peptide, suggesting they are cytotoxic T cells (data not shown). Re-stimulation by autologous APCs or AAPCs increased similarly expression of immuno-regulation molecules as T cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin and mucin- domain containing-3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1 (data not shown).
Discussion:
In this study, we have developed novels AAPCs that endogenously express Ag in several compartments involved in MHC II pathway. We identified AAPCDR1 encoding HA peptide in the ER and AAPCDR1 encoding HA membrane protein as the most effective cells to present Ag. Previously, with AAPCs expressing HLA-I molecules we have demonstrated that addressing a peptide Ag in the ER using the signal sequence of the CD8a molecule is a very reliable strategy to trigger CTL responses.21 Similarly, the high efficiency of peptide encoding AAPCdr1 in ER may explain by an optimal loading of HA peptide into nascent MHC-II molecule in absence of the chaperone protein Ii that blocks peptide cleft. The potent Ag presentation ability of AAPCDR1 expressing HA protein at the cell membrane may result of the recycling of HA proteins and HLA-DR1 molecules. Indeed, it has been already demonstrated in professional APCs but also in fibroblasts that some HA epitopes can be generated into early endosomes which contain MHC-II recycled molecules and unfolding HA protein that have underwent mild proteolysis, independently of Ii and HLA-DM present in the MIIC.24-26 Conversely, the weak Ag presentation ability of protein-encoding AAPCs targeting endosome could be linked to a high proteolysis activity that does not lead to the generation of the appropriate HA epitope. In accordance with this hypothesis, Kim et al described that the HA306- 318 epitope was highly sensitive to the digestion by cathepsins.27 AAPCs expressing peptide or protein in extracellular media were less efficient to present Ag than AAPCs targeting ER or the plasma membrane likely because of a low level of endocytosis. AAPCs expressing HA protein
or peptide in the cytosol are the weakest stimulating cells. This may explain by a inappropriate proteasome cleavage of HA protein and/or a weak TAP (Transporter associated with Antigen Processing) transport of the HA peptide in ER due to their sequence and length that do not fit common features of HLA-I ligands.28,29
Although AAPCs expressing HA peptide in ER or protein in membrane as well as AAPCs loaded with HA peptide have strong Ag presentation capacity, they activate effector CD4+ T cells after primary stimulation but at lower level than autologous APCs. It is likely that endogenous expression of HA Ag is not sufficient to hamper presentation of xenopeptide competitors and so to limit non-specific CD4+ T cell responses. To prevent the access of xenopeptides in the ER, a promising approach is to induce expression of the TAP inhibitors such as UL49.5 and US6 viral proteins of AAPCDR1 by gene transfer.30 The xenopeptides presented by HLA-DR1 molecules can also arise from autophagy mechanisms.31,32 Autophagy represents an important source of endogenous peptides presented on MHC-II molecules.33 Blockade of this mechanism using specific inhibitors such as bafilomycin Al, could decrease the binding of xenopeptides on MHC-II molecules.34 Moreover, to increase priming ability of AAPCdr1, it will be interesting to generate an AAPCDR1 cell line expressing both HA peptide in the ER and HA protein at the cell surface.
Interestingly, targeting approach of HA peptide in ER is an efficient strategy to obtain a higher number of Ag-specific CD4+ T cells than with AAPCs or autologous APCs loaded with HA peptide. Effector T cells harbor a strong Thl profil with high production of IFN-g and TNF-a, that is a relevant property for anti-tumor immunotherapy.35 In addition, we identified a subset of CD4+ T cells that express granzyme B but not perforin. This expression was already reported as a Thl memory cells characteristic.36 Further studies are needed to evaluate the function of this subset. However, whatever the stimulating cells, expanded specific CD4+ T cells express immuno-regulation molecules as TIGIT, TIM-3, PD-1 and CTLA-4 that could limit their functionality in vivo. It was shown that CTL based ACI efficiency was improved by immune checkpoints blockades combination.37,38 It likely that the same therapeutic approach is required for ACI replying in part on effector CD4+ T cells. AAPCs could also be modified to express appropriate costimulation signals that improve CD4+ TLs survival and functionality. For this purpose, CD70 and 4-1BBL molecules are two promising candidates. Indeed, the CD27/CD70 costimulatory signaling pathway has been reported to promotes Thl polarization but also CD4+ TLs survival.39 On the other hand, interaction between 4-1BB and 4-1BBL molecules favors proliferation and effector functions like cytolytic activity of activated CD4+ TLs.40-42
In this study we confirmed that AAPCs is a suitable tool to generate an absolute number of functional specific CD4+ TLs compatible for ACI protocols.14 We also show that HA protein-encoding AAPCDR1 are efficient to process whole Ag and generate peptide epitopes. This property could be exploited to identify new T CD4+ epitopes from therapeutic interest Ags by HLA-II/peptide complexes immunoprecipitation of AAPCDR1, coupled to mass spectrometry analysis.43 In parallel, AAPCDR1 expressing endogenous or exogenous Ag could be a reliable tool to monitor human T CD4+ responses in vitro.44 In conclusion, based on Ag-encoding AAPCdr1, we have developed an in vitro protocol enabling a rapid and robust amplification of functional memory Thl cells for future ACI applications.
REFERENCES:
Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
1. Borst J, Ahrends T, Bqbala N, Melief CJM, Kastenmiiller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 2018; 18: 635-647.
2. Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat Rev Immunol 2016; 16: 102D 11.
3. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441: 890D3.
4. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 2008; 105: 5201 D6.
5. Ahrends T, Spanjaard A, Pilzecker B, Bqbala N, Bovens A, Xiao Y, et al. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity 2017; 47: 848-861. e5.
6. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, et al. Thl7 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35: 972D 85.
7. Quezada S A, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor- reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637D 50.
8. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18: 1248 D 53.
9. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698□ 703.
10. Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21: 81 D 5.
11. Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut 2017; 66: 454□ 63.
12. Sun Z, Chen F, Meng F, Wei J, Liu B. MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Cancer Lett 2017; 392: 17D25.
13. Tran E, Turcotte S, Gros A, Robbins PF, Lu Y-C, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344: 641□ 5.
14. Gamier A, Hamieh M, Drouet A, Leprince J, Vivien D, Frebourg T, et al. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Immunol Cell Biol 2016; 94: 662D72.
15. Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011; 11: 823□ 36.
16. ten Broeke T, Wubbolts R, Stoorvogel W. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harb Perspect Biol 2013; 5: aO 16873.
17. Sadegh-Nasseri S. A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. FlOOOResearch 2016; 5.
18. Ahangarani RR, Janssens W, VanderElst L, Carlier V, VandenDriessche T, Chuah M, et al. In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL- 10-dependent antigen-specific unresponsiveness. J Immunol 2009; 183: 8232D43.
19. Wang S, Bartido S, Yang G, Qin J, Moroi Y, Panageas KS, et al. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol 1999; 163: 5820D6.
20. Tan NS, Ho B, Ding JL. Engineering a novel secretion signal for cross-host recombinant protein expression. Protein Eng 2002; 15: 337D45.
21. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18: 405□ 9.
22. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl AcadSci 1996; 93: 11400D6.
23. Cole DK, Gallagher K, Lemercier B, Holland CJ, Junaid S, Hindi ey JP, et al. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nat Commun 2012; 3: 665.
24. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995; 375: 603 D6.
25. Tewari MK, Sinnathamby G, Rajagopal D, Eisenlohr LC. A cytosolic pathway for MHC class Il-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol 2005; 6: 287□ 94.
26. Sinnathamby G, Eisenlohr LC. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. J Immunol 2003; 170: 3504D 13.
27. Kim A, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, et al. Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nat Commun 2014; 5: 5369.
28. Geng J, Pogozheva ID, Mosberg HI, Raghavan M. Use of Functional Polymorphisms To Elucidate the Peptide Binding Site of TAP Complexes. J Immunol 2015; 195: 3436D48.
29. Lam TH, Mamitsuka H, Ren EC, Tong JC. TAP Hunter: a SVM-based system for predicting TAP ligands using local description of amino acid sequence. Immunome Res 2010; 6 Suppl 1: S6
30. Verweij MC, Ressing ME, Knetsch W, Quinten E, Halenius A, van Bel N, et al. Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol Immunol 2011; 48: 835□ 45.
31. Eisenlohr LC, Luckashenak N, Apcher S, Miller MA, Sinnathamby G. Beyond the classical: influenza virus and the elucidation of alternative MHC class Il-restricted antigen processing pathways. Immunol Res 2011; 51: 237D48.
32. Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 2015; 15: 203 D 16.
33. Adamopoulou E, Tenzer S, Hillen N, Klug P, Rota IA, Tietz S, et al. Exploring the MHC-peptide matrix of central tolerance in the human thymus. Nat Commun 2013; 4: 2039.
34. Yang Y, Hu L, Zheng H, Mao C, Hu W, Xiong K, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin 2013; 34: 625 D35.
35. Kayser S, Bob C, Feucht J, Witte K-E, Scheu A, Biilow H-J, et al. Rapid generation of NY-ESO-1 -specific CD4+ THELPERl cells for adoptive T-cell therapy. Oncoimmunology 2015; 4: el002723.
36. Lin L, Couturier J, Yu X, Medina MA, Kozinetz CA, Lewis DE. Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells. BMC Immunol 2014; 15: 36.
37. Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, etal. T-Cell Therapy Using Interleukin-21 -Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol 2016; 34: 3787D95.
38. Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, et al. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol 2018; 8: 44.
39. van Oosterwijk MF, Juwana H, Arens R, Tesselaar K, van Oers MHJ, Eldering E, et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Thl cell development. Int Immunol 2007; 19: 713 D 8.
40. Wen T, Bukczynski J, Watts TH. 4- IBB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168: 4897□ 906.
41. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, et al. 4- IBB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD 8 T cells with similar efficacy. J Immunol 2001; 167: 1313 D24.
42. Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, et al. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity. J Immunol 2016; 196: 484D92.
43. Heyder T, Kohler M, Tarasova NK, Haag S, Rutishauser D, Rivera NV, et al. Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples. Mol Cell Proteomics MCP 2016; 15: 3017D29.
44. Gilardin L, Delignat S, Peyron I, Ing M, Lone Y-C, Gangadharan B, et al. The ADAMTS131239-1253 peptide is a dominant HLA-DR1 -restricted CD4+ T-cell epitope. Haematologica 20\1 ; 102: 1833 D41.
45. Abelin G. J, Harjanto D, Malloy M, Sun Pr, Colson T,. Goulding S. P, L. Creech A, Serrano L. R., Nasir G, Nasrullah Y, McGann C. D., Velez D, Ting Y. S., Poran A, A.
Rothenberg D, Chhangawala S, Rubinsteyn A, Hammerbacher J,. Gaynor R. B, Fritsch E F., Greshock J, Oslund R. C., Barthelme D,. Addona T. A, Arieta C. M. and Rooney M. S. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity 51, 766-779.
Claims
1. An artificial antigen presenting cell consisting of a eucaryotic cell that is genetically modified to stably express a single MHC class II molecule, at least one accessory molecule and at least one antigen.
2. The artificial antigen presenting cell of claim 1 wherein the eucaryotic cell is a murine fibroblast.
3. The artificial antigen presenting cell of claim 1 wherein the MHC class II molecule is selected from the group consisting of HLA-DQ molecules, HLA-DP molecules and HLA-DR molecules.
4. The artificial antigen presenting cell of claim 1 of claim 1 wherein the MHC class II molecule is selected from the group consisting of HLA-DRl, HLA-DR15 and HLA- DR51 molecules.
5. The artificial antigen presenting cell of claim 1 wherein the eucaryotic cell is genetically modified to stably express the CD80, CD54 and CD58 molecules.
6. The artificial antigen presenting cell of claim 1 wherein the eucaryotic cell is genetically modified to stably express a peptide antigen in the endoplasmic reticulum (ER).
7. The artificial antigen presenting cell of claim 1 wherein the eucaryotic cell is genetically modified to stably express a protein antigen in the endosomes or in the membrane.
8. The artificial antigen presenting cell of claim 6 wherein the eucaryotic cell is genetically modified to stably express the antigen peptide fused to a signal sequence.
9. The artificial antigen presenting cell of claim 8 wherein the signal peptide is the signal peptide of the T cell surface glycoprotein CD8 alpha chain.
10. The artificial antigen presenting cell of claim 9 wherein the signal peptide has the amino acid sequence as forth in SEQ ID NO: 1.
11. The artificial antigen presenting cell of claim 1 wherein the antigen is a viral antigen, a bacterial antigen, a fimgal antigen, a protozoal antigen, a tumor associated antigen, an auto-antigen, or an allergen.
12. A method of preparing the artificial antigen presenting cell of claim 1 wherein the eucaryoticn cell is a transfected with a vector encoding for the antigen, at least one vector encoding for the accessory molecule and a vector encoding for the MHC class II molecule.
13. The method of claim 12 wherein a vector comprising a nucleic acid sequence encoding for the signal peptide operatively linked to a nucleic acid sequence encoding for the antigen peptide is used to stably express the antigen peptide into the endoplasmic reticulum of the eucaryotic cell.
14. The method of claim 13 wherein the nucleic acid sequence encoding for the signal peptide consists of the nucleic acid sequence as set forth in SEQ ID NO: 2.
15. The method of claim 12 wherein the vector are gamma retroviral vectors
16. A method of amplifying a population of antigen-specific CD4+ T cells comprising the steps of coculturing a population of a T cells with the population of artificial antigen presenting cells of claim 1
17. The method of claim 16 wherein the population of AAPCs is irradiated before incubation with the population of CD4 T cells.
18. The method of claim 16 which further comprise a step consisting of polarizing the antigen-specific CD4+ T cells into a population of antigen-specific T regulatory cells.
19. A population of antigen-specific CD4+ T cells obtainable by the method of claim 16.
20. A method of treatment in a subject in need thereof comprising administering to the subject the population of antigen-specific CD4+ T cells of claim 19.
21. The method of claim 20 for the treatment of cancer, infectious disease, autoimmune disease, or allergy
22. The method of claim 20 for the treatment of immune reactions against a grafted tissue or grafted hematopoietic cells or grafted blood cells.
23. A method of identifying a population of CD4+ T cells within a test population of T cells comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i) and iii) detecting whether a population of CD4+ T cells is activated and/or amplified.
24. A method of determining identifying and/or characterizing the T cell epitopes of an antigen comprising the steps of i) providing a population of artificial antigen presenting cells that express the antigen, ii) coculturing the population of T cells with the population of artificial antigen presenting cells of step i), iii) detecting whether a population of CD4+ T cells is activated and/or amplified, iv) selecting the population of artificial antigen presenting cells that is capable of activating and/or amplifying the population of CD4+ T cells, v) recovering and characterizing the peptides from the MHC class II molecules wherein said peptides represent the T cell epitopes of the antigen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306685 | 2018-12-13 | ||
EP18306685.1 | 2018-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020120649A1 true WO2020120649A1 (en) | 2020-06-18 |
Family
ID=65628496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/084788 WO2020120649A1 (en) | 2018-12-13 | 2019-12-12 | Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020120649A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
WO1989005345A1 (en) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
US4868116A (en) | 1985-07-05 | 1989-09-19 | Whitehead Institute For Biomedical Research | Introduction and expression of foreign genetic material in epithelial cells |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
WO1992007573A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
-
2019
- 2019-12-12 WO PCT/EP2019/084788 patent/WO2020120649A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868116A (en) | 1985-07-05 | 1989-09-19 | Whitehead Institute For Biomedical Research | Introduction and expression of foreign genetic material in epithelial cells |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
WO1989005345A1 (en) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
WO1992007573A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
Non-Patent Citations (90)
Title |
---|
"A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage", NAT. MED., vol. 13, no. 2, 2007, pages 139 - 145 |
ABELIN G. JHARJANTO DMALLOY MSURI PRCOLSON TGOULDING S. PL. CREECH ASERRANO L. R.NASIR GNASRULLAH Y: "Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction", IMMUNITY, vol. 51, pages 766 - 779 |
ADAMOPOULOU ETENZER SHILLEN NKLUG PROTA IATIETZ S ET AL.: "Exploring the MHC-peptide matrix of central tolerance in the human thymus", NAT COMMUN, vol. 4, 2013, pages 2039 |
AGRAWAL ET AL., J. HEMATOTHER. STEM CELL RES., 2000, pages 795 - 812 |
AHANGARANI RRJANSSENS WVANDERELST LCARLIER VVANDENDRIESSCHE TCHUAH M ET AL.: "In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness", JIMMUNOL, vol. 183, no. 8232, 2009, pages 43 |
AHRENDS TSPANJAARD APILZECKER BBABALA NBOVENS AXIAO Y ET AL.: "CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness", IMMUNITY, vol. 47, 2017, pages 848 - 861 |
AKHMETZYANOVA IZELINSKYY GLITTWITZ-SALOMON EMALYSHKINA ADIETZE KKSTREECK H ET AL.: "CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity", J IMMUNOL, vol. 196, no. 484, 2016, pages 92 |
ARMENTANO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 6141 - 6145 |
BARBOSA JAMENTZER SJKAMARCK MEHART JBIRO PASTROMINGER JLBURAKOFF SJ: "Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions", J. IMMUNOL., vol. 136, no. 8, April 1986 (1986-04-01), pages 3085 - 91 |
BATTAGLIA ET AL., J. IMMUNOL., vol. 177, 2006, pages 8338 - 8347 |
BORST J ET AL: "CD4+T cell help in cancer immunology and immunotherapy", NATURE REVIEWS IMMUNOLOGY, vol. 18, no. 10, 29 July 2018 (2018-07-29), pages 635 - 647, XP036602043, ISSN: 1474-1733, DOI: 10.1038/S41577-018-0044-0 * |
BORST JAHRENDS TBABALA NMELIEF CJMKASTENMULLER W: "CD4+ T cell help in cancer immunology and immunotherapy", NAT REV IMMUNOL, vol. 18, no. 63, 2018, pages 5 - 647 |
BOSHART ET AL., CELL, vol. 41, 1985, pages 521 |
BUTLER M O ET AL: "A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles", INTERNATIONAL IMMUNOLOGY, vol. 22, no. 11, November 2010 (2010-11-01), pages 863 - 873, XP055386975, ISSN: 0953-8178, DOI: 10.1093/intimm/dxq440 * |
CANNONS JLLAU PGHUMMAN BDEBENEDETTE MAYAGITA HOKUMURA K ET AL.: "4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy", J IMMUNOL, vol. 167, no. 1313, 2001, pages 24 |
CARLSON MNAKAMURA YPAYSON RO'CONNELL PLEPPERT MLATHROP GMLALOUEL JMWHITE R: "Isolation and mapping of a polymorphic DNA sequence (pMCT108.2) on chromosome 18 D18S24", NUCLEIC ACIDS RES., vol. 16, no. 9, May 1988 (1988-05-01), pages 4188 |
CHAPUIS AGROBERTS IMTHOMPSON JAMARGOLIN KABHATIA SLEE SM ET AL.: "T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression", J CLIN ONCOL, vol. 34, no. 3787, 2016, pages 95 |
CHATILLON J-F ET AL: "Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies : TLR8 engagement increases CTL function", IMMUNITY, INFLAMMATION AND DISEASE, vol. 3, no. 1, March 2015 (2015-03-01), pages 1 - 13, XP055594829, ISSN: 2050-4527, DOI: 10.1002/iid3.43 * |
CHATTOPADHYAY ET AL., NAT.MED., vol. 11, 2005, pages 1118 |
CHOWDHURY ET AL., SCIENCE, vol. 254, 1991, pages 1802 - 1805 |
COLE DKGALLAGHER KLEMERCIER BHOLLAND CJJUNAID SHINDLEY JP ET AL.: "Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection", NAT COMMUN, vol. 3, 2012, pages 665 |
COURNOYER ET AL., ANNU. REV. IMMUNOL., vol. 11, 1993, pages 297 - 329 |
COUTURE A ET AL: "HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 10, 17 May 2019 (2019-05-17), XP055594828, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01081 * |
DIJKEMA ET AL., EMBO J., vol. 4, 1985, pages 761 |
DUPONT J ET AL: "Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells", CANCER RESEARCH, vol. 65, no. 12, 15 June 2005 (2005-06-15), pages 5417 - 5427, XP002355479, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2991 * |
EGLITIS ET AL., SCIENCE, vol. 230, 1985, pages 1395 - 1398 |
EISENLOHR LCLUCKASHENAK NAPCHER SMILLER MASINNATHAMBY G: "Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways", IMMUNOL RES, vol. 51, no. 237, 2011, pages 48 |
FERRY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 8377 - 8381 |
GARNIER A ET AL: "Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4 + T cells", IMMUNOLOGY AND CELL BIOLOGY, vol. 94, no. 7, August 2016 (2016-08-01), pages 662 - 672, XP055594821, ISSN: 0818-9641, DOI: 10.1038/icb.2016.25 * |
GARNIER AHAMIEH MDROUET ALEPRINCE JVIVIEN DFREBOURG T ET AL.: "Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells", IMMUNOL CELL BIOL, vol. 94, no. 662, 2016, pages 72 |
GENG JPOGOZHEVA IDMOSBERG HIRAGHAVAN M: "Use of Functional Polymorphisms To Elucidate the Peptide Binding Site of TAP Complexes", J IMMUNOL, vol. 195, no. 3436, 2015, pages 48 |
GILARDIN LDELIGNAT SPEYRON IING MLONE Y-CGANGADHARAN B ET AL.: "The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope", HAEMATOLOGICA, vol. 102, no. 1833, 2017, pages 41 |
GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6777 |
GREGORI ET AL., BLOOD, vol. 116, 2009, pages 935 - 944 |
HERRMANN, J. MOL. MED., vol. 73, 1995, pages 157 - 63 |
HEYDER TKOHLER MTARASOVA NKHAAG SRUTISHAUSER DRIVERA NV ET AL.: "Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples", MOL CELL PROTEOMICS MCP, vol. 15, no. 3017, 2016, pages 29 |
HUNDER NNWALLEN HCAO JHENDRICKS DWREILLY JZRODMYRE R ET AL.: "Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1", NENGL JMED, vol. 358, no. 2698, 2008, pages 703 |
HWU ET AL., J. IMMUNOL., vol. 150, 1993, pages 4104 - 4115 |
KATZ FEPARKAR MSTANLEY KMURRAY LJCLARK EAGREAVES MF: "Chromosome mapping of cell membrane antigens expressed on activated B cells", EUR. J. IMMUNOL., vol. 15, no. 1, January 1985 (1985-01-01), pages 103 - 6 |
KAY ET AL., HUMAN GENE THERAPY, vol. 3, 1992, pages 641 - 647 |
KAYSER SBOO CFEUCHT JWITTE K-ESCHEU ABIILOW H-J ET AL.: "Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy", ONCOIMMUNOLOGY, vol. 4, 2015, pages e 1002723 |
KIM AHARTMAN IZPOORE BBORONINA TCOLE RNSONG N ET AL.: "Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources", NAT COMMUN, vol. 5, 2014, pages 5369 |
KIM ET AL., GENE, vol. 185, 1990, pages 217 |
KIRSCHMEIER ET AL., DNA, vol. 7, 1988, pages 219 - 225 |
LAIDLAW BJCRAFT JEKAECH SM: "The multifaceted role of CD4(+) T cells in CD8(+) T cell memory", NAT REV IMMUNOL, vol. 16, 2016, pages 102011 |
LAM THMAMITSUKA HREN ECTONG JC: "TAP Hunter: a SVM-based system for predicting TAP ligands using local description of amino acid sequence", IMMUNOME RES, vol. 6, no. 1, 2010, pages 6 |
LATOUCHE J-B ET AL: "Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells", NATURE BIOTECHNOLOGY, vol. 18, no. 4, April 2000 (2000-04-01), pages 405 - 409, XP002191046, ISSN: 1087-0156, DOI: 10.1038/74455 * |
LATOUCHE JBSADELAIN M: "Induction of human cytotoxic T lymphocytes by artificial antigenpresenting cells", NAT BIOTECHNOL, vol. 18, 2000, pages 405 - 9 |
LATOUCHE JBSADELAIN M: "Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells", NAT BIOTECHNOL, vol. 18, no. 405, 2000, pages 9 |
LEISNER ET AL., PLOSONE, vol. 3, 2008, pages el678 |
LIN LCOUTURIER JYU XMEDINA MAKOZINETZ CALEWIS DE: "Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells", BMC IMMUNOL, vol. 15, 2014, pages 36, XP021200170, DOI: 10.1186/s12865-014-0036-1 |
LINNEMANN CVAN BUUREN MMBIES LVERDEGAAL EMESCHOTTE RCALIS JJA ET AL.: "High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma", NAT MED, vol. 21, no. 81, 2015, pages 5 |
MANNERING ET AL., J.IMMUNOL.METHODS, vol. 283, 2003, pages 173 |
MENNONNA DMACCALLI CROMANO MCGARAVAGLIA CCAPOCEFALO FBORDONI R ET AL.: "T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes", GUT, vol. 66, no. 454, 2017, pages 63 |
MILLER, BLOOD, vol. 76, 1990, pages 1437 - 1500 |
MIZUSHIMA ET AL., NAGATA, NUC. ACIDS. RES., vol. 18, 1990, pages 5322 |
MULLINAX JEHALL MPRABHAKARAN SWEBER JKHUSHALANI NEROGLU Z ET AL.: "Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma", FRONT ONCOL, vol. 8, 2018, pages 44 |
MURANSKI PBORMAN ZAKERKAR SPKLEBANOFF CAJI YSANCHEZ-PEREZ L ET AL.: "Th17 cells are long lived and retain a stem cell-like molecular signature", IMMUNITY, vol. 35, 2011, pages 972, XP028348604, DOI: 10.1016/j.immuni.2011.09.019 |
NEEFJES JJONGSMA MLMPAUL PBAKKE O: "Towards a systems understanding of MHC class I and MHC class II antigen presentation", NAT REV IMMUNOL, vol. 11, no. 823, 2011, pages 36 |
NOVAK ET AL., J.CLIN.INVEST., vol. 104, 1999, pages 63 |
OH SPERERA LPTERABE MNI LWALDMANN TABERZOFSKY JA: "IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis", PROC NATL ACAD SCI USA, vol. 105, 2008, pages 5201D6 |
ORY DSNEUGEBOREN BAMULLIGAN RC: "A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes", PROC NATL ACAD SCI, vol. 93, no. 11400, 1996, pages 6 |
PEACH, R JBAJORATH JNAEMURA JLEYTZE GGREENE JARUFFO ALINSLEY P S: "Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28", J. BIOL. CHEM. (UNITED STATES, vol. 270, no. 36, September 1995 (1995-09-01), pages 21181 - 7, XP002912152, DOI: 10.1074/jbc.270.36.21181 |
PINET VVERGELLI MMARTIN RBAKKE OLONG EO: "Antigen presentation mediated by recycling of surface HLA-DR molecules", NATURE, vol. 375, no. 603, 1995, pages 6 |
PRICE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 156 - 160 |
PURWAR RSCHLAPBACH CXIAO SKANG HSELYAMAN WJIANG X ET AL.: "Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells", NAT MED, vol. 18, no. 1248, 2012, pages 53 |
PUTNAM ET AL., DIABETES, vol. 58, 2009, pages 652 - 662 |
QUEZADA SASIMPSON TRPEGGS KSMERGHOUB TVIDER JFAN X ET AL.: "Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts", J EXP MED, vol. 207, no. 637, 2010, pages 50 |
ROCHE PAFURUTA K: "The ins and outs of MHC class II-mediated antigen processing and presentation", NAT REV IMMUNOL, vol. 15, no. 203, 2015, pages 16 |
SADEGH-NASSERI S: "A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells", FLOOORESEARCH, 2016, pages 5 |
SINNATHAMBY GEISENLOHR LC: "Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification", J IMMUNOL, vol. 170, no. 3504, 2003, pages 13 |
STAMPER, C CZHANG YTOBIN J FERBE D VIKEMIZU SDAVIS S JSTAHL M LSEEHRA JSOMERS W SMOSYAK L: "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses", NATURE (ENGLAND, vol. 410, no. 6828, March 2001 (2001-03-01), pages 608 - 11, XP002328138, DOI: 10.1038/35069118 |
SUN ZCHEN FMENG FWEI JLIU B: "MHC class II restricted neoantigen: A promising target in tumor immunotherapy", CANCER LETT, vol. 392, no. 17, 2017, pages 25 |
TAN NSHO BDING JL: "Engineering a novel secretion signal for cross-host recombinant protein expression", PROTEIN ENG, vol. 15, no. 337, 2002, pages 45 |
TEN BROEKE TWUBBOLTS RSTOORVOGEL W: "MHC class II antigen presentation by dendritic cells regulated through endosomal sorting", COLD SPRING HARB PERSPECT BIOL, vol. 5, 2013, pages a016873 |
TEWARI MKSINNATHAMBY GRAJAGOPAL DEISENLOHR LC: "A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent", NAT IMMUNOL, vol. 6, no. 287, 2005, pages 94 |
TOBIAS MAETZIGMELANIE GALLACHRISTOPHER BAUMAXEL SCHAMBACH: "Gammaretroviral Vectors: Biology, Technology and Application", VIRUSES, vol. 3, no. 6, June 2011 (2011-06-01), pages 677 - 713 |
TRAN ETURCOTTE SGROS AROBBINS PFLU Y-CDUDLEY ME ET AL.: "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer", SCIENCE, vol. 344, no. 641, 2014, pages 5 |
UETSUKI ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5791 |
VAN BEUSECHEM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10892 - 10895 |
VAN DE STOLPE ET AL., J. MOL. MED., vol. 74, 1996, pages 13 - 33 |
VAN OOSTERWIJK MFJUWANA HARENS RTESSELAAR KVAN OERS MHJELDERING E ET AL.: "CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Thl cell development", INT IMMUNOL, vol. 19, no. 713, 2007, pages 8 |
VERWEIJ MCRESSING MEKNETSCH WQUINTEN EHALENIUS AVAN BEL N ET AL.: "Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses", MOL/IMMUNOL, vol. 48, no. 835, 2011, pages 45 |
VOSS ET AL., TRENDS BIOCHEM. SCI., vol. 11, 1986, pages 287 |
WALLICH RBRENNER CBRAND YROUX MREISTER MMEUER S: "Gene structure, promoter characterization, and basis for alternative mRNA splicing of the human CD58 gene", J. IMMUNOL., vol. 160, no. 6, 15 March 1998 (1998-03-15), pages 2862 - 71 |
WANG SBARTIDO SYANG GQIN JMOROI YPANAGEAS KS ET AL.: "A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses", J IMMUNOL, vol. 163, no. 5820, 1999, pages 6 |
WEN TBUKCZYNSKI JWATTS TH: "4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function", J IMMUNOL, vol. 168, no. 4897, 2002, pages 906 |
WILLIAMS MATYZNIK AJBEVAN MJ: "Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells", NATURE, vol. 441, 2006, pages 89003 |
WILSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 3014 - 3018 |
YANG YHU LZHENG HMAO CHU WXIONG K ET AL.: "Application and interpretation of current autophagy inhibitors and activators", ACTA PHARMACOL SIN, vol. 34, no. 625, 2013, pages 35 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7397791B2 (en) | Gene editing of primary cells | |
JP2023162369A (en) | Neoantigen identification for t-cell therapy | |
US20210104294A1 (en) | Method for predicting hla-binding peptides using protein structural features | |
CN112368386A (en) | Consensus antigens | |
KR20200087143A (en) | Identification of new antigens using hot spots | |
KR20200127001A (en) | Identification of neoantigens with pan-allele model | |
TW201907937A (en) | Alpha virus new antigen vector | |
Ryan et al. | Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses | |
TW202100168A (en) | Identification of neoantigens with mhc class ii model | |
TWI733719B (en) | Improved compositions and methods for viral delivery of neoepitopes and uses thereof | |
WO2020072700A1 (en) | Hla single allele lines | |
US20180355316A1 (en) | Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules | |
US20220273712A1 (en) | Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy | |
CN114072516A (en) | Modified adenoviruses | |
WO2020131586A2 (en) | Methods for identifying neoantigens | |
JP2023017853A (en) | Novel cancer antigens and methods | |
CN117279660A (en) | Modified alphavirus vectors | |
AU2020371619A1 (en) | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells | |
EP4303233A1 (en) | Targeted protein degradation system and use thereof | |
Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
KR20220029560A (en) | Novel cancer antigens and methods | |
KR20220029561A (en) | Novel cancer antigens and methods | |
WO2020120649A1 (en) | Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule | |
WO2023049733A2 (en) | Methods and composition using patient-derived autologous neoantigens for treating cancer | |
WO2022192789A1 (en) | Genetically modified cells expressing antigen-containing fusion proteins and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19816743 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19816743 Country of ref document: EP Kind code of ref document: A1 |